EXECUTION VERSION

 


STOCK PURCHASE AGREEMENT

by and among

Masthercell Global Inc.,

Orgenesis Inc.,

and

GPP-II Masthercell, LLC

 

Dated June 28, 2018


TABLE OF CONTENTS

        Page
         
ARTICLE 1 PURCHASE AND SALE OF COMPANY PREFERRED STOCK 1
     
  1.1 Basic Transaction 1
  1.2 Purchase Price 2
  1.3 Estimated Cash Payment 2
  1.4 Payment and Delivery of Purchase Price 2
  1.5 Cash Payment Determination 3
  1.6 Calculation of Future Payments 3
  1.7 Determination of Future Payments 5
  1.8 Calculations 6
  1.9 Closing 6
  1.10 Israel Sub and South Korea Sub 6
       
ARTICLE 2 REPRESENTATIONS AND WARRANTIES CONCERNING TRANSACTION 7
     
  2.1 Representations and Warranties of Orgenesis Parent 7
  2.2 Representations and Warranties of Investor 8
         
ARTICLE 3 REPRESENTATIONS AND WARRANTIES CONCERNING THE COMPANY AND ITS SUBSIDIARIES 11
     
  3.1 Organization, Qualification, and Power 11
  3.2 Authorization of Transaction 11
  3.3 Capitalization and Subsidiaries 12
  3.4 Non-contravention 13
  3.5 Brokers’ Fees 13
  3.6 Assets   13
  3.7 Financial Statements; Interim Conduct 14
  3.8 Undisclosed Liabilities 16
  3.9 Legal Compliance 17
  3.10 Tax Matters   17
  3.11 Real Property 19
  3.12 Intellectual Property 20
  3.13 Contracts   22
  3.14 Insurance   24
  3.15 Litigation   24
  3.16 Employees   25
  3.17 Employee Benefits 25
  3.18 Debt   26
  3.19 Environmental, Health, and Safety Matters 26
  3.20 Business Continuity 27
  3.21 Certain Business Relationships with the Company and its Subsidiaries 28
  3.22 Customers and Vendors 28
  3.23 Product Warranty 29
  3.24 Product Liability 29

-i-


TABLE OF CONTENTS (continued)

  Page
         
  3.25 Information Privacy and Data Security 30
         
ARTICLE 4 POST-CLOSING COVENANTS 30
     
  4.1 General 30
  4.2 Litigation Support 30
  4.3 Transition 31
  4.4 Confidentiality 31
  4.5 Covenant Not to Compete 31
  4.6 Covenant Not to Solicit 31
  4.7 Enforcement 32
  4.8 Release   33
  4.9 Israel Sub and South Korea Sub 33
  4.10 Stockholders’ Agreement Terms 33
  4.11 QMS License Agreement 34
         
ARTICLE 5 CLOSING DELIVERIES 34
     
  5.1 Closing Deliveries of Orgenesis Parent 34
  5.2 Closing Deliveries of Investor 36
         
ARTICLE 6 REMEDIES FOR BREACHES OF THIS AGREEMENT 36
     
  6.1 Indemnification by Orgenesis Parent 36
  6.2 Indemnification by Investor 37
  6.3 Survival and Time Limitations 37
  6.4 Limitations on Indemnification by Orgenesis Parent 37
  6.5 Limitations on Indemnification by Investor 38
  6.6 Third-Party Claims 38
  6.7 Other Indemnification Matters 39
  6.8 Indemnity Payments 40
         
ARTICLE 7 TAX MATTERS 40
     
  7.1 Tax Indemnification 40
  7.2 Responsibility for Filing Tax Returns for Periods through Closing Date 41
  7.3 Straddle Periods 41
  7.4 Cooperation on Tax Matters 41
  7.5 Certain Taxes 41
         
ARTICLE 8 DEFINITIONS 41
         
ARTICLE 9 MISCELLANEOUS 54
     
  9.1 Press Releases and Public Announcements 54
  9.2 No Third-Party Beneficiaries 54
  9.3 Entire Agreement 54
  9.4 Succession and Assignment 54

-ii-


TABLE OF CONTENTS (continued)

        Page
         
  9.5 Counterparts   55
  9.6 Headings   55
  9.7 Notices   55
  9.8 Governing Law 57
  9.9 Amendments and Waivers 57
  9.10 Injunctive Relief 57
  9.11 Severability   58
  9.12 Expenses   58
  9.13 Construction   58
  9.14 Incorporation of Exhibits and Disclosure Schedule 58
  9.15 Schedules   58
  9.16 Waiver of Jury Trial 58
  9.17 Exclusive Venue 59
  9.18 Time to Bring Claims 59

-iii-



EXHIBITS AND SCHEDULES
 
Exhibit A Advisory Services Agreements
     
Exhibit B Amended and Restated Certificate of Incorporation
     
Exhibit C Employment Agreement
     
Exhibit D Stockholders’ Agreement
     
Disclosure Schedule Exceptions to Representations and Warranties
     
Schedule 1.3 Certificate for Balance Sheet and Estimated Cash Payment and Related Components
     
Schedule 1.4(a)(ii) Debt Paid at Closing
     
Schedule 1.8 Methodology of Calculation of Working Capital, Net Income, EBITDA and Net Revenue
     
Schedule 5.1(b) Consents Under Contracts and Permits
     
Schedule 5.1(g) Resignations at Closing
     
Schedule 5.1(i) Debt
     
Schedule 5.1(m) Related Party Agreements Terminated at Closing
     
Schedule 8.1 Sample Calculation of Working Capital
     
Schedule 9.1 Press Release

- i -


STOCK PURCHASE AGREEMENT

This Stock Purchase Agreement (this “Agreement”) is entered into on June 28, 2018 by and among GPP-II Masthercell, LLC, a Delaware limited liability company (“Investor”), Masthercell Global Inc., a Delaware corporation (the “Company”), and Orgenesis Inc., a Nevada corporation (“Orgenesis Parent”). Investor, the Company, and Orgenesis Parent are referred to collectively herein as the “Parties” and individually as a “Party”.

PRELIMINARY STATEMENTS

In connection with the purchase of the Company Preferred Stock by Investor, and concurrently therewith, Orgenesis Parent consummated a reorganization (the “Reorganization”) pursuant to which Orgenesis Parent contributed, or caused to be contributed, to the Company (i) 83.32% of the equity interests of MaSTherCell S.A., a company organized under the laws of Belgium, (ii) all of the equity interests of Cell Therapy Holding S.A., a company organized under the laws of Belgium, (iii) all of the equity interests of Atvio Biotech Ltd., a company organized under the laws of Israel (the “Israel Sub”) (which shall be owned by the Company within four (4) Business Days after the date hereof), (iv) 94.12% of the equity interests of CureCell Co., Ltd., a Korean stock corporation (the “South Korea Sub”) (which shall be owned by the Company within four (4) Business Days after the date hereof), and (v) all other assets related to or used in the Business.

Immediately prior to the Closing, Orgenesis Parent owns all of the outstanding equity interests of the Company. Investor desires to make an equity investment in the Company on the date hereof pursuant to which the Company will issue certain equity interests to Investor and Orgenesis Parent desires to cause the Company to accept such investment and issue such equity interests to Investor, upon the terms and subject to the conditions set forth in this Agreement. Consequently, immediately after the Closing, Orgenesis Parent and Investor will own all of the outstanding equity interests of the Company.

The Parties shall treat the purchase of the Company Preferred Stock and the Reorganization as part of the same plan of reorganization pursuant to Section 351 of the Code.

AGREEMENT

Now, therefore, in consideration of the premises and the mutual promises herein made, and in consideration of the representations, warranties, covenants and other valuable consideration herein contained, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

ARTICLE 1

PURCHASE AND SALE OF COMPANY PREFERRED STOCK

1.1       Basic Transaction. In accordance with the terms and upon the conditions of this Agreement and concurrently with the Reorganization, at the Closing the Company shall issue, and Investor shall purchase, 378,000 shares of Series A Preferred Stock of the Company, par value $0.0001 per share (the “Company Preferred Stock”) to Investor, free and clear of all Liens, such shares representing 37.8% of the share capital of the Company on a fully diluted basis as of the Closing Date.     


1.2       Purchase Price. The purchase price for the Company Preferred Stock (the “Purchase Price”) shall consist of:

(a)       the Cash Payment, subject to adjustment as provided in this Article 1; plus

(b)       the Future Payments (if any), to the extent payable in accordance with Section 1.4(c).

1.3       Estimated Cash Payment. Attached hereto as Schedule 1.3 is a certificate signed by an officer of Orgenesis Parent which (a) attaches a balance sheet of the Company and (b) sets forth Orgenesis Parent’s best estimate of the Debt Amount, the Working Capital and Working Capital Deficit, if any, and the Cash Shortfall, if any, in each case as of the Closing Date and, based on such estimates, the Cash Payment (the “Estimated Cash Payment”), and as of the date hereof Orgenesis Parent has delivered to Investor all records and work papers as requested by Investor and reasonably necessary to compute and verify the information set forth in such certificate, all of which must be reasonably acceptable to Investor.

1.4       Payment and Delivery of Purchase Price.

(a)       Closing Payments. At the Closing, Investor shall:

(i)       pay the Estimated Cash Payment to the Company; and

(ii)       pay the Debt Amount set forth on Schedule 1.4(a)(ii) pursuant to the payoff letters delivered by Orgenesis Parent to Investor pursuant to Section 5.1(i).

(b)       Cash Payment Adjustment. Within five (5) Business Days after the Cash Payment becomes final and binding in accordance with Section 1.5, if ninety-five percent (95%) of the Estimated Cash Payment exceeds the Final Cash Payment (the amount of such excess, the “Cash Payment Shortfall”), then Orgenesis Parent shall pay an amount equal to the Cash Payment Shortfall to the Company in cash.

(c)       Future Payments. Within ten (10) days after the Future Payments become final and binding in accordance with Section 1.7, Investor shall pay such Future Payments, if any, to the Company.

(d)       Payments. All payments to the Company pursuant to this Section 1.4 shall be made by wire transfer of immediately available funds to an account designated by the Company in writing.

(e)       Withholding. The Parties and any other applicable withholding agent of Investor will be entitled to deduct and withhold from any amounts payable pursuant to or contemplated by this Agreement any Taxes required to be deducted and withheld under the Code or any applicable Law, and, to the extent that any amounts are so deducted or withheld, such amounts will be treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction and withholding was made.

-2-


1.5       Cash Payment Determination. Within ninety (90) days after the Closing Date, the Company shall prepare and deliver to the Investor a statement setting forth the Company’s calculation of the Debt Amount, the Working Capital and Working Capital Deficit, if any, and the Cash Shortfall, if any, in each case as of the Closing Date and, based on such calculations, the Cash Payment (the “Closing Statement”). If the Investor has any objections to the Closing Statement prepared by the Company based on the contention that such Closing Statement was not prepared in accordance with the terms of the Agreement, then the Investor will deliver a detailed written statement (the “Objections Statement”) describing (a) which items on the Closing Statement have not been prepared in accordance with this Agreement, (b) the basis for the Investor’s disagreement with the calculation of such items and (c) the Investor’s proposed dollar amount for each item in dispute, to the Company within thirty (30) days after delivery of the Closing Statement. If the Investor fails to deliver an Objections Statement within such thirty (30) day period, then the Closing Statement shall become final and binding on all Parties. The Investor and the Company shall be deemed to have agreed with all amounts and items contained or reflected in the Closing Statement to the extent such amounts or items are not disputed in the Objections Statement. If the Investor delivers an Objections Statement within such thirty (30) day period, then the Investor and the Company will use commercially reasonable efforts to resolve any such disputes, but if a final resolution is not obtained within thirty (30) days after the Investor has submitted any Objections Statements, any remaining matters which are in dispute will be resolved by BDO USA, LLP (the “Accountants”). The Accountants will prepare and deliver a written report to the Investor and the Company and will submit a proposed resolution of such unresolved disputes promptly, but in any event within thirty (30) days after the dispute is submitted to the Accountants. The Accountants’ determination of such unresolved disputes shall be final and binding upon all Parties and not subject to review by a court or other tribunal; provided, however, that no such determination shall be any more favorable to the Company than is set forth in the Closing Statement or any more favorable to the Investor than is proposed in the Objections Statement. The costs, expenses and fees of the Accountants shall be borne by the Party whose calculation of the Cash Payment has the greatest difference from the Final Cash Payment as determined by the Accountants under this Section 1.5; otherwise, such costs, fees and expenses shall be borne equally by the Investor, on the one hand, and the Company, on the other hand. The final Closing Statement, however determined pursuant to this Section 1.5, will produce the Working Capital Deficit, if any, the Cash Shortfall, if any, and the Debt Amount to be used to determine the final Cash Payment (the “Final Cash Payment”).

1.6       Calculation of Future Payments.

(a)       If, during any twelve month period ending on or prior to December 31, 2018 (the “First Measurement Period”), the Company and its Subsidiaries generate Net Revenue equal to or greater than €14,100,000 and EBITDA equal to or greater than €1,800,000 (collectively, both such Net Revenue and EBITDA targets are the “First Milestones”), and the shareholders of Orgenesis Parent have approved the Stockholders’ Agreement Terms prior to December 31, 2018 in accordance with Law and in a manner that will ensure that Investor is able to exercise its rights under the Stockholders’ Agreement without any further action or approval by Investor, Orgenesis Parent, the shareholders of Orgenesis Parent, or any other Person (collectively, “Proper Approval”, and the act of providing such Proper Approval shall be referred to as “Properly Approved”), then Investor shall make a payment to the Company equal to $6,600,000 (subject to potential adjustment in accordance with Section 1.6(d), the “First Future Payment”) within ten (10) days from the date such First Future Payment becomes final and binding in accordance with Section 1.7. For the avoidance of doubt, if (i) the Company and its Subsidiaries fail to reach either of the First Milestones, or (ii) the shareholders of Orgenesis Parent have not Properly Approved the Stockholders’ Agreement Terms prior to December 31, 2018, then the First Future Payment shall be zero (0); provided, that if both of the First Milestones have been reached but the shareholders of Orgenesis Parent have not Properly Approved the Stockholders’ Agreement Terms prior to December 31, 2018, if at any time prior to December 31, 2019 the shareholders of Orgenesis Parent do Properly Approve the Stockholders’ Agreement Terms, then the First Future Payment shall become payable at that time. For the sake of clarity, the terms “Proper Approval” and “Properly Approved” shall not include any secondary or additional approval that may be required after the Proper Approval has been obtained (and if such Proper Approval has been obtained, any secondary or additional approval that may subsequently be required shall not cause the Stockholders’ Agreement Terms to be deemed not Properly Approved by the shareholders of Orgenesis) and the First Future Payment and the Second Future Payment are not, and shall not, be conditioned upon receiving any such secondary or additional approval of the Stockholders’ Agreement Terms from the shareholders of Orgenesis Parent as may be required by Law at a later date.

-3-


Notwithstanding the foregoing, in the event that (a) the Company and its Subsidiaries fail to reach either or both of the EBITDA or Net Revenue First Milestones during the First Measurement Period (with such shortfalls being referred to as a “First Period EBITDA Shortfall” or a “First Period Net Revenue Shortfall”, as applicable), and (b) the Company and its Subsidiaries achieves both the EBITDA and the Net Revenue Second Milestones during the Second Measurement Period, and (c) to the extent there was a First Period EBITDA Shortfall the Company and its Subsidiaries generate EBITDA during the Second Measurement Period that exceeds the EBITDA Second Milestone by an amount that is equal to, or greater than, such First Period EBITDA Shortfall and (d) to the extent there was a First Period Net Revenue Shortfall the Company and its Subsidiaries generate Net Revenue during the Second Measurement Period that exceeds the Net Revenue Second Milestone by an amount that is equal to, or greater than, such Net Revenue Shortfall, then (if the shareholders of Orgenesis Parent have Properly Approved the Stockholders’ Agreement Terms prior to December 31, 2019) the First Future Payment shall become payable at that time.

(b)       If, during any twelve month period ending on or prior to December 31, 2019 (the “Second Measurement Period”), the Company and its Subsidiaries generate Net Revenue equal to or greater than €19,100,000 and EBITDA equal to or greater than €3,900,000 (collectively, both such Net Revenue and EBITDA targets are the “Second Milestones”), and the shareholders of Orgenesis Parent have Properly Approved the Stockholders’ Agreement Terms, then Investor shall make a payment to the Company equal to $6,600,000 (subject to potential adjustment in accordance with Section 1.6(d), the “Second Future Payment”) within ten (10) days from the date such Second Future Payment becomes final and binding in accordance with Section 1.7. For the avoidance of doubt, if (i) Net Revenue generated by the Company and its Subsidiaries during the Second Measurement Period is less than €19,100,000, or (ii) EBITDA generated by the Company and its Subsidiaries during the Second Measurement Period is less than €3,900,000, or (iii) the shareholders of Orgenesis Parent have not Properly Approved the Stockholders’ Agreement Terms prior to the end of the Second Measurement Period, then the Second Future Payment shall be zero (0).

-4-


(c)       In the event Orgenesis Parent fails to obtain Proper Approval of the Stockholders’ Agreement Terms in accordance with Nevada law on or before December 31, 2019, the Parties agree that Orgenesis Parent shall not be entitled to the First Future Payment or the Second Future Payment and such Future Payments shall be zero (0).

(d)       The Investor may, in its sole discretion and at any time, regardless of whether the conditions required for payment of the First Future Payment and/or the Second Future Payment as set forth in Sections 1.6(a) and 1.6(b) have been achieved, choose to pay all or a portion of the First Future Payment or the Second Future Payment to the Company; provided, that in the event the Investor does make such a payment to the Company, the amount of any required unpaid Future Payments shall be reduced by an amount equal to such payment (beginning first with reduction of the Second Future Payment and after the Second Future Payment has been reduced to zero (0), then reduction of the First Future Payment). For example, if the Investor makes a payment to the Company pursuant to this Section 1.6(d) in an amount equal to $1,000,000 and the conditions set forth in Section 1.6(b) are achieved such that the Second Future Payment becomes payable, then the Second Future Payment that would be payable in such event would be equal to $5,600,000.

1.7       Determination of Future Payments. Within one hundred twenty (120) days after the end of each of the First Measurement Period and the Second Measurement Period, the Company shall prepare and deliver to the Investor a report (each, a “Future Payment Report”) containing the unaudited financial statements of the Company and its Subsidiaries on a consolidated basis for the applicable Measurement Period and setting forth the Company’s calculation of Net Revenue and EBITDA generated by the Company and its Subsidiaries during such Measurement Period and the resulting First Future Payment or Second Future Payment, as applicable. If the Investor has any objections to the calculation of Net Revenue or EBITDA generated by the Company and its Subsidiaries during the applicable Measurement Period and the resulting First Future Payment or Second Future Payment prepared by the Company, then the Investor will deliver a detailed written statement (each, a “Future Payment Objections Statement”) describing its objections to the Company within thirty (30) days after delivery of the applicable Future Payment Report. If the Investor fails to deliver the applicable Future Payment Objections Statement within such thirty (30) day period, then the calculation of Net Revenue and EBITDA generated by the Company and its Subsidiaries during the applicable Measurement Period and the resulting applicable Future Payment set forth in the applicable Future Payment Report shall become final and binding on all Parties. If the Investor delivers the applicable Future Payment Objections Statement within such thirty (30) day period, then the Investor and the Company will use commercially reasonable efforts to resolve any such disputes, but if a final resolution is not obtained within thirty (30) days after the Investor has submitted the applicable Future Payment Objections Statement, any remaining matters which are in dispute will be resolved by the Accountants. The Accountants will prepare and deliver a written report to the Company and the Investor and will submit a resolution of such unresolved disputes promptly, but in any event within thirty (30) days after the dispute is submitted to the Accountants. The Accountants’ determination of such unresolved disputes shall be final and binding upon all Parties; provided, however, that no such determination shall be any more favorable to the Company than is set forth in the applicable Future Payment Report or any more favorable to the Investor than is proposed in the applicable Future Payment Objections Statement. The costs, expenses and fees of the Accountants shall be borne by the Party whose calculation of the First Future Payment or Second Future Payment, as applicable, has the greatest difference from the final First Future Payment or Second Future Payment, as applicable, as determined by the Accountants under this Section 1.7; otherwise, such costs, fees and expenses shall be borne equally by the Investor, on the one hand, and the Company, on the other hand. Upon the First Future Payment and the Second Future Payment, as applicable, becoming final and binding in accordance with this Section 1.7, the Investor shall pay such First Future Payment (if any) and such Second Future Payment (if any), as applicable, to the Company in accordance with Section 1.4(c).

-5-


1.8       Calculations. All calculations of Working Capital, Net Income, EBITDA and Net Revenue under this Agreement, whether estimates or otherwise, shall be determined in accordance with GAAP except as otherwise provided in the definitions of Working Capital, Net Income, EBITDA and Net Revenue and as set forth on Schedule 1.8.

1.9       Closing. The closing of the transactions contemplated by this Agreement (the “Closing”) shall take place simultaneously on the date the Reorganization is complete, all deliverables set forth in Sections 5.1 and 5.2 are provided by the Parties, and payment of the Estimated Cash Payment is made by the Investor to the Company pursuant to the terms of this Agreement on the date of this Agreement (the “Closing Date”). The Parties may execute this Agreement electronically by the mutual exchange of facsimile or portable document format (.PDF) signatures on the Closing Date. All transactions contemplated herein to occur on and as of the Closing Date shall be deemed to have occurred simultaneously and to be effective as of 12:01 a.m. Chicago time on such date.

1.10       Israel Sub and South Korea Sub. In the event that the Company does not own one hundred percent (100%) of the equity interests of (a) the South Korea Sub and (b) the Israel Sub on or prior to the one (1) year anniversary of the Closing Date, (i) Orgenesis Parent shall, during the period that the Company owns equity interests of the South Korea Sub and the Israel Sub, as applicable, pay to the Company in immediately available funds an amount equal to any portion of any dividend or distribution paid by the South Korea Sub or the Israel Sub that the Company does not receive due to the Company not having ownership of one hundred percent (100%) of the equity interests of the South Korea Sub and the Israel Sub, as applicable and (ii) upon a Sale of the Company (as defined in the Stockholders’ Agreement) or any sale or transfer of equity interests of the South Korea Sub or the Israel Sub, Investor shall receive proceeds as a result of such transaction (the “Subsidiary Proceeds”) in an amount equal to the product of (x) the value of the equity interests of the South Korea Sub or the Israel Sub, as applicable, that are not owned by the Company multiplied by (y) the percentage representing Investor’s ownership of the total share capital of the Company on a fully diluted basis as of the time of such transaction, and the amount of such Subsidiary Proceeds shall be deducted from the proceeds that Orgenesis Parent is entitled to receive as a result of such transaction.

-6-


ARTICLE 2

REPRESENTATIONS AND WARRANTIES CONCERNING TRANSACTION

2.1       Representations and Warranties of Orgenesis Parent. Orgenesis Parent, on behalf of itself only, represents and warrants to Investor that the statements contained in this Section 2.1 are correct and complete as of the Closing Date, except as set forth in the corresponding section of the Disclosure Schedule. The Parties hereby agree that any items, references or disclosures made in the Disclosure Schedule shall be subject to Section 9.15.

(a)       Authorization of Transaction. Orgenesis Parent is duly formed, validly existing and in good standing under the Laws of the State of Nevada. Orgenesis Parent has full power, authority and legal capacity to execute and deliver this Agreement and the Ancillary Agreements to which Orgenesis Parent is a party and to perform Orgenesis Parent’s obligations hereunder and thereunder and to complete the Reorganization concurrently with the investment contemplated by this Agreement. The execution and delivery by Orgenesis Parent of this Agreement and the Ancillary Agreements to which Orgenesis Parent is a party and the completion of the Transactions have been duly approved by all requisite action of Orgenesis Parent. Assuming the due authorization, execution and delivery of this Agreement and the Ancillary Agreements by the other parties thereto, this Agreement and each Ancillary Agreement to which Orgenesis Parent is a party constitute the valid and legally binding obligation of Orgenesis Parent, enforceable against Orgenesis Parent in accordance with their terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws affecting creditors generally and by the availability of equitable remedies. Except as set forth on Section 2.1(a) of the Disclosure Schedule, Orgenesis Parent is not required to give any notice to, make any filing with, or obtain any Consent of any Governmental Body or any other Person in connection with the consummation of the Transactions.

(b)       Non-contravention. Except as set forth in Section 2.1(b) of the Disclosure Schedule, the execution and the delivery of this Agreement and the Ancillary Agreements to which Orgenesis Parent is a party, and the consummation of the Transactions, will not (i) violate or conflict with any Law or Order to which Orgenesis Parent is subject, (ii) conflict with, result in a breach of, constitute a default under, result in the acceleration of, create in any party the right to accelerate, terminate, modify, or cancel, or require any notice or Consent under any Contract to which Orgenesis Parent is a party or by which Orgenesis Parent or any of its Subsidiaries is bound or to which any of Orgenesis Parent’s or assets is subject, (iii) result in the imposition or creation of a Lien upon or with respect to the Company Preferred Stock or any asset of Orgenesis Parent, or (iv) violate any provision of the Organizational Documents of Orgenesis Parent.

(c)       Brokers’ Fees. Orgenesis Parent has no liability or obligation to pay any fees or commissions to any broker, finder, or agent with respect to this Agreement or any Ancillary Agreement or the Transactions.

(d)       Company Securities. At the Closing, the Company will issue the Company Preferred Stock to Investor, free and clear of any Liens. Neither Orgenesis Parent nor the Company is a party to, and the Company Securities are not subject to, any option, warrant, purchase right or other Contract or commitment that could require the Company or Orgenesis Parent to sell, transfer, or otherwise dispose of any Company Securities or any other equity interests of the Company (other than this Agreement). Other than as set forth in the Stockholders’ Agreement, neither Orgenesis Parent nor the Company is a party to any voting trust, proxy or other Contract with respect to the voting of any Company Securities or any other equity interests of the Company.

-7-


(e)       Litigation. Orgenesis Parent is not engaged in or a party to or, to the Knowledge of Orgenesis Parent, threatened with any complaint, charge, Proceeding, Order or other process or procedure for settling disputes or disagreements with respect to the Company or any of its Subsidiaries or the Transactions, and Orgenesis Parent has not received written or, to the Knowledge of Orgenesis Parent, oral notice of a claim or dispute that is reasonably likely to result in any such complaint, charge, Proceeding, Order or other process or procedure for settling disputes or disagreements with respect to the Company or any of its Subsidiaries or the Transactions.

(f)       Reorganization. Orgenesis Parent has full power, authority and legal capacity to execute the documents and consummate the transactions necessary to effectuate the Reorganization. The execution of the documents and consummation of the transactions necessary to effectuate the Reorganization have been duly approved by all requisite action of Orgenesis Parent. All assets (tangible and intangible), properties and rights owned or developed, in whole or in part, by Orgenesis Parent in connection with the operation of the Business or owned or licensed by Orgenesis Parent and used in the operation of the Business any time during the twelve (12) months prior to Closing, have been properly transferred, at Closing and concurrently with the investment contemplated by this Agreement, free and clear of all Liens to the Company and its Subsidiaries as a result of the Reorganization.

(g)       Subsidiaries. Orgenesis Parent represents that each of its applicable Subsidiaries has taken the necessary actions (including the execution and delivery of all necessary documents and agreements), and received the necessary approvals, required to consummate the Transactions (including the Reorganization) and that such actions and the consummation of the Transactions will not (i) violate or conflict with any Law or Order to which any of the Subsidiaries of Orgenesis Parent is subject, (ii) conflict with, result in a breach of, constitute a default under, result in the acceleration of, create in any party the right to accelerate, terminate, modify, or cancel, or require any notice or Consent under any Contract to which any such Subsidiary is a party or by which any such Subsidiary is bound or to which any of their assets is subject, (iii) result in the imposition or creation of a Lien upon or with respect to any asset of any such Subsidiary, or (iv) violate any provision of the Organizational Documents of any such Subsidiary. All assets (tangible and intangible), properties and rights owned, licensed or developed, in whole or in part, by any of the Subsidiaries of Orgenesis Parent that are required to operate the Business or used in the operation of the Business any time during the twelve (12) months prior to Closing, have been properly transferred free and clear of all Liens to the Company or one of its Subsidiaries as a result of the Reorganization.

2.2       Representations and Warranties of Investor. Investor represents and warrants to the Company and Orgenesis Parent that the statements contained in this Section 2.2 are correct and complete as of the Closing Date.

-8-


(a)       Organization of Investor. Investor is a limited liability company duly formed, validly existing and in good standing under the Laws of the State of Delaware.

(b)       Authorization of Transaction. Investor has full power and authority to execute and deliver this Agreement and the Ancillary Agreements to which Investor is a party and to perform Investor’s obligations hereunder and thereunder. The execution and delivery by Investor of this Agreement and the Ancillary Agreements to which Investor is a party and the performance by Investor of the Transactions have been duly approved by all requisite entity level action of Investor. Assuming the due authorization, execution and delivery of this Agreement and the Ancillary Agreements by the other parties thereto, this Agreement and each Ancillary Agreement to which Investor is a party constitute the valid and legally binding obligation of Investor, enforceable against Investor in accordance with their terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws affecting creditors generally and by the availability of equitable remedies. Investor is not required to give any notice to, make any filing with, or obtain any Consent of any Governmental Body or any other Person in order to consummate the Transactions.

(c)       Non-contravention. Neither the execution and the delivery of this Agreement nor the Ancillary Agreements to which Investor is a party, nor the consummation of the Transactions, will (i) violate or conflict with any Law or Order to which Investor is subject, (ii) violate any provision of the Organizational Documents of Investor or (iii) conflict with, result in a breach of, constitute a default under, result in the acceleration of, create in any party the right to accelerate, terminate, modify, or cancel, or require any notice or Consent under any Contract to which Investor is a party or by which it is bound or to which any of its assets is subject.

(d)       Brokers’ Fees. Investor does not have any liability or obligation to pay any fees or commissions to any broker, finder or agent with respect to the Transactions for which Orgenesis Parent or the Company could become liable or obligated.

(e)       Investment. Investor is not acquiring the Company Preferred Stock with a view to or for sale in connection with any distribution thereof within the meaning of the Securities Act.

(f)       Accredited Investor Status; Investment Experience. Investor is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act. The Investor has such knowledge and experience in financial and business matters such that the Investor is capable of evaluating the merits and risks of an investment in the Company Preferred Stock, or has consulted with advisors who possess such knowledge and experience. The Investor is able to bear the economic risk and a complete loss of its investment in the Company for an indefinite period of time.

(g)       Reliance on Exemptions. Investor understands that the Company Preferred Stock and any other capital stock into which such Company Preferred Stock is convertible (collectively, the “Securities”) are being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company and Orgenesis Parent are relying in part upon the truth and accuracy of, and Investor’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of Investor set forth herein in order to determine the availability of such exemptions and the eligibility of such Investor to acquire the Securities.

-9-


(h)       Information. Investor acknowledges that it has received all of the information it considers necessary or appropriate for deciding whether to acquire the Securities. Investor and its advisors, if any, have been afforded the opportunity to ask questions of the Company.

(i)       No Government Review. Investor understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

(j)       Transfer or Resale. Investor understands that: (i) the Securities have not been and may not being registered under the Securities Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder, (B) Investor shall have delivered to the Company (if requested by the Company) an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C) Investor provides the Company with reasonable assurance that such Securities can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the Securities Act (or a successor rule thereto) (collectively, “Rule 144”); (ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144, and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and regulations of the U.S. Securities and Exchange Commission promulgated thereunder; and (iii) except as set forth in the Stockholders’ Agreement, neither the Company nor any other Person is under any obligation to register the Securities under the Securities Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder unless otherwise agreed to by the Company and Investor.

(k)       Investor (i) shall treat the purchase of the Company Preferred Stock and the Reorganization as part of a plan of reorganization pursuant to Section 351 of the Code (the “Tax Treatment”); and (ii) will, and will cause its Affiliates to, prepare and file all applicable Tax Returns required to be filed by Investor or its Affiliates with any Governmental Authority in any manner consistent with the Tax Treatment and to take no position inconsistent with the Tax Treatment in any applicable Tax Return or in any proceeding before any Governmental Authority, unless otherwise required by applicable Law.

(l)       There is no Contract of Investor to (i) dispose of the Company Preferred Stock issued pursuant to this Agreement, (ii) require the Company to redeem any of the Company Preferred Stock held by Investor (other than pursuant to the redemption rights set forth in the Stockholders’ Agreement and the Company’s Certificate of Incorporation), or (iii) require the Company to issue to Investor any stock of the Company for services rendered to, or for the benefit of, the Company in connection with the proposed transaction.

-10-


Nothing contained in this Section 2.2, nor any breach by Investor of any of its representations contained in this Section 2.2, shall limit, modify, amend or affect in any way Investor’s right (i) to rely on the representations and warranties contained in this Agreement or (ii) to receive indemnification from Orgenesis Parent in connection with any breach of any representations and warranties contained in this Agreement. For the sake of clarity, nothing in this paragraph shall derogate from, or limit, any of the restrictions, exclusions or limitations to Investor’s right to receive indemnification from Orgenesis Parent set forth in Section 4.10, Article 6 and Section 9.15.

ARTICLE 3

REPRESENTATIONS AND WARRANTIES CONCERNING THE COMPANY AND ITS SUBSIDIARIES

The Company represents and warrants to Investor that the statements contained in this Article 3 are correct and complete as of the Closing Date, except as set forth in the corresponding section of the Disclosure Schedule.

3.1       Organization, Qualification, and Power. Section 3.1(a) of the Disclosure Schedule sets forth the jurisdiction of incorporation or formation of the Company and each of its Subsidiaries and each state or other jurisdiction in which the Company and each of its Subsidiaries is licensed or qualified to do business. The Company and each of its Subsidiaries are duly organized, validly existing and in good standing under the Laws of their respective jurisdictions of incorporation or formation. The Company and each of its Subsidiaries are duly authorized to conduct their business and are in good standing under the Laws of each jurisdiction where such qualification is required. The Company and each of its Subsidiaries have full power and authority and all Permits necessary to carry on the businesses in which they are engaged and to own, lease and use the properties owned, leased and used by them. Section 3.1(b) of the Disclosure Schedule lists the board of directors, managers, management board and officers, as the case may be, of the Company and each of its Subsidiaries. The Company has delivered to Investor correct and complete copies of the Organizational Documents, the minute book and equity interest record books for the Company and each of its Subsidiaries, each of which is correct and complete. Neither the Company nor any of its Subsidiaries is in default under or in violation of any provision of their Organizational Documents.

3.2       Authorization of Transaction. The Company and each of its Subsidiaries has full power, authority and legal capacity to execute and deliver the Agreement and the Ancillary Agreements to which it is a party and to perform its obligations hereunder and thereunder and to complete the Reorganization. The execution and delivery by the Company and its Subsidiaries of the Agreement and the Ancillary Agreements to which it is a party and the performance by the Company and its Subsidiaries of the Transactions have been duly approved by all requisite entity level action of the Company and its Subsidiaries. Assuming the due authorization, execution and delivery of this Agreement and the Ancillary Agreements by the other parties thereto, this Agreement and each Ancillary Agreement to which the Company and its Subsidiaries are a party constitute the valid and legally binding obligation of the Company and such Subsidiaries (as the case may be), enforceable against the Company and such Subsidiaries (as the case may be) in accordance with their terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws affecting creditors generally and by the availability of equitable remedies. Except as set forth on Section 3.2 of the Disclosure Schedule, neither the Company nor any of its Subsidiaries is required to give any notice to, make any filing with, or obtain any Consent of any Governmental Body or any other Person in connection with the consummation of the Transactions.

-11-


3.3       Capitalization and Subsidiaries.

(a)       622,000 shares of Common Stock of the Company, par value $0.0001 per share (the “Company Common Stock”) are owned beneficially and of record by Orgenesis Parent and Orgenesis Parent has good and indefeasible title to all of the Company Common Stock free and clear of all Liens. Upon the Closing, (i) the Company Preferred Stock shall be owned beneficially and of record by Investor, (ii) the Company Common Stock and the Company Preferred Stock (collectively, the “Company Securities”) shall represent one hundred percent (100%) of the outstanding equity or other ownership interests in the Company, and (iii) all of the Company Securities shall have been duly authorized, validly issued, fully paid, and shall be non-assessable and shall have been issued without violation of any preemptive right or other right to purchase. There are no outstanding securities convertible or exchangeable into equity or other ownership interests of the Company, and other than as set forth in the Stockholders’ Agreement, there are no options, warrants, purchase rights, subscription rights, conversion rights, exchange rights, calls, puts, rights of first refusal or other Contracts that could require the Company to issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem equity or other ownership interests in the Company. There are no outstanding or authorized equity appreciation, phantom equity, profit participation or similar rights with respect to the Company. Other than as set forth in the Stockholders’ Agreement, there are no voting trusts, proxies or other Contracts with respect to the voting of the equity or other ownership interests of the Company. Upon the Closing, the Company Preferred Stock will be delivered to Investor free and clear of all Liens, and Investor will have good and marketable title to the Company Preferred Stock.

(b)       All of the Subsidiaries, direct and indirect, of the Company are listed in Section 3.3(b)(i) of the Disclosure Schedule. Section 3.3(b)(i) of the Disclosure Schedule lists the entire authorized stock, equity or other ownership interests of each such Subsidiary and the record and beneficial owner of such stock, equity or other ownership interests, all of which have been duly authorized, are validly issued, fully paid and non-assessable and have been issued without violation of any preemptive right or other right to purchase. The Company owns, directly or indirectly, all of the stock, equity or other ownership interests of the Subsidiaries listed in Section 3.3(b)(i) of the Disclosure Schedule, free and clear of all Liens except as set forth in Schedule 3.3(b)(i) of the Disclosure Schedule. There are no outstanding securities convertible or exchangeable into stock, equity or other ownership interests of any such Subsidiary, and there are no options, warrants, purchase rights, subscription rights, conversion rights, exchange rights, calls, puts, rights of first refusal or other Contracts that could require any such Subsidiary to issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem stock, equity or other ownership interests in any such Subsidiary. There are no outstanding or authorized equity appreciation, phantom appreciation, profit participation or similar rights with respect to any Subsidiary required to be listed on Section 3.3(b)(i) of the Disclosure Schedule. There are no voting trusts, proxies or other Contracts with respect to the voting of the stock, equity or other ownership interests of any such Subsidiary.

-12-


(c)       Notwithstanding anything contained in this Agreement or in any section of the Disclosure Schedule, within four (4) Business Days after the date hereof, (i) the Company owns beneficially and of record free and clear of all Liens (A) 83.32% of the equity interests of MaSTherCell S.A., a company organized under the laws of Belgium, (B) all of the equity interests of Cell Therapy Holding S.A., a company organized under the laws of Belgium, (C) all of the equity interests of Israel Sub and (D) all of the equity interests of South Korea Sub other than the shares of South Korea Sub referenced in Section 3.3(b)(i) of the Disclosure Schedule, (ii) the Company has the full and unrestricted right to acquire all of the shares of South Korea Sub referenced in Section 3.3(b)(i) of the Disclosure Schedule promptly after the Closing Date and any amounts payable to or obligations owed to the holder of such shares in connection with the acquisition of such shares shall be the sole responsibility of Orgenesis Parent, (iii) there are no outstanding securities convertible or exchangeable into stock, equity or other ownership interests of any of the Company’s Subsidiaries, and there are no options, warrants, purchase rights, subscription rights, conversion rights, exchange rights, calls, puts, rights of first refusal or other Contracts that could require any such Subsidiary to issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem stock, equity or other ownership interests in any such Subsidiary, (iv) there are no amounts payable by the Company or any of its Subsidiaries to any former equityholder of any Subsidiary of the Company in connection with (A) the acquisition of equity interests from such former equityholder or (B) the Reorganization, and (v) any amounts payable to any former equityholder of any Subsidiary of the Company in connection with (A) the acquisition of equity interests from such former equityholder or (B) the Reorganization are obligations of Orgenesis Parent.

3.4       Non-contravention. Neither the execution and the delivery of this Agreement and the Ancillary Agreements to which the Company or any of its Subsidiaries is a party, nor the consummation of the Transactions, will (i) violate or conflict with any Law or Order to which the Company or any of its Subsidiaries is subject, (ii) violate or conflict with any provision of the Organizational Documents of the Company or any of its Subsidiaries, or (iii) conflict with, result in a breach of, constitute a default under, result in the acceleration of, create in any party the right to accelerate, terminate, modify, or cancel, or require any notice, Consent or payment under any Contract or Permit to which the Company or any of its Subsidiaries is a party or by which it is bound or to which any of its assets is subject (or result in the imposition or creation of any Lien upon or with respect to any of its assets).

3.5       Brokers’ Fees. Except as set forth on Section 3.5 of the Disclosure Schedule, neither the Company nor any of its Subsidiaries has any liability or obligation to pay any fees or commissions to any broker, finder, or agent with respect to the Transactions.

3.6       Assets.

(a)       The Company and its Subsidiaries have good and marketable title to, or a valid leasehold interest or license in, all of the assets (tangible and intangible), properties and rights used in the operation of the Business or developed for use, in whole or in part, in connection with the Business, free and clear of all Liens, except for Permitted Liens. The assets, properties and rights owned by the Company and its Subsidiaries are all the assets, properties and rights necessary to operate the Businesses, consistent with past practice.

-13-


(b)       The buildings, machinery, equipment and other tangible assets that the Company and its Subsidiaries own and lease are free from material defects (patent and latent), have been maintained in all material respects in accordance with normal industry practice, are in good operating condition and repair (subject to normal wear and tear) and are suitable for the purposes for which they are presently used. None of the personal or moveable property owned or leased by the Company or any of its Subsidiaries is located at any facility other than the Leased Real Property.

3.7       Financial Statements; Interim Conduct.

(a)       Attached to Section 3.7(a)(i) of the Disclosure Schedule are correct and complete copies of the following financial statements of the Company and its Subsidiaries (collectively, the “Financial Statements”): (i) unaudited consolidated balance sheets, statements of income, equityholders’ equity and cash flows as of and for the fiscal years ended November 31, 2015 and November 31, 2016 (the “Most Recent Fiscal Year End”) after giving pro forma effect to the Reorganization; (ii) unaudited consolidated balance sheets, statements of income, equityholders’ equity and cash flows (the “Most Recent Financial Statements”) as of and for the fiscal year ended November 30, 2017 and as of and for the three (3) month period ended February 28, 2018 (the “Most Recent Fiscal Month End”) after giving pro forma effect to the Reorganization, and (iii) unaudited balance sheets, statements of income, equityholders’ equity and cash flows as of and for the year to date period ended April 30, 2018 for MaSTherCell S.A. only. The Financial Statements are correct and complete and consistent with the books and records of the Company and its Subsidiaries (which are in turn correct and complete), have been prepared in accordance with GAAP consistently applied, do not reflect any revenue or assets other than those used in the Business, and present fairly in all material respects the financial condition, results of operation, changes in equity and cash flow of the Company and its Subsidiaries as of and for their respective dates and for the periods then ending after giving effect to the Reorganization on a pro forma basis; provided, however, that the Most Recent Financial Statements are subject to normal, recurring year-end adjustments and lack notes (none of which will be material individually or in the aggregate). Section 3.7(a)(ii) of the Disclosure Schedule sets forth (x) a schedule setting forth all pro forma adjustments made to the Financial Statements in order to give pro forma effect to the Reorganization and (y) a reasonably detailed description of all adjustments that were made to Orgenesis Parent’s internal financial statements when preparing the Financial Statements (including the amount of each such adjustment and the methodology utilized in its determination). All adjustments set forth on Section 3.7(a)(ii) of the Disclosure Schedule are reasonable and were prepared in good faith by Orgenesis Parent. The Financial Statements do not reflect or include any revenues other than revenue generated from the operation of the Business and do not reflect or include any assets other than assets owned, at the time of Closing, by the Company or its Subsidiaries and used in the Business. Section 3.7(a)(iii) of the Disclosure Schedule sets forth the budget for the Company and its Subsidiaries for the three (3) month period ended May 31, 2018 and the operations and performance of the Company and its Subsidiaries during such period has been materially consistent with such budget.

-14-


(b)       Since the Most Recent Fiscal Year End, the Business has been conducted in the Ordinary Course of Business, and there has not been any Material Adverse Effect and no event has occurred which could reasonably be expected to result in a Material Adverse Effect. Except as set forth on Section 3.7(b) of the Disclosure Schedule, since the Most Recent Fiscal Year End neither the Company, nor any of its Subsidiaries, nor the Business has:

(i)       sold, leased, transferred or assigned any assets or property (tangible or intangible) with a value in excess of $25,000 (or $100,000 in the aggregate), other than sales of inventory in the Ordinary Course of Business;

(ii)       experienced any damage, destruction or loss (whether or not covered by insurance) to its assets or property (tangible or intangible) in excess of $25,000 (or $100,000 in the aggregate);

(iii)       accelerated, terminated, cancelled or allowed to expire any Contract, which, if in existence on the date hereof, would be required to be listed on Section 3.13 of the Disclosure Schedule or received notice from any Person regarding the acceleration, termination, modification or cancellation of a Contract required to be listed on Section 3.13 of the Disclosure Schedule;

(iv)      issued, created, incurred, assumed or guaranteed any Debt;

(v)       forgave, cancelled, compromised, waived or released any Debt owed to it or any right or claim except for resolving its accounts receivable in the Ordinary Course of Business;

(vi)       issued, sold or otherwise disposed of any of its equity or other ownership interests, or granted any options, warrants or other rights to acquire (including upon conversion, exchange or exercise) any of its equity or other ownership interests or declared, set aside, made or paid any dividend or distribution with respect to its equity or other ownership interests or redeemed, purchased or otherwise acquired any equity or other ownership interest or amended or made any change to any of its Organizational Documents or made any other payment to its members or equityholders (or any Affiliates of such members or equityholders);

(vii)       granted any increase in salary, wages or bonus or otherwise increased the compensation or benefits payable or provided to any director, manager, officer, employee, consultant, advisor or agent;

(viii)       engaged in any promotional, sales or discount or other activity that has or could reasonably be expected to have the effect of accelerating sales or receivables prior to the Closing that would otherwise be expected to occur subsequent to the Closing;

(ix)       made any commitment outside of the Ordinary Course of Business or in excess of $25,000 in the aggregate for capital expenditures to be paid after the Closing or failed to incur capital expenditures in accordance with its capital expense budget;

-15-


(x)        incurred any material liability or obligation;

(xi)       instituted any material change in the conduct of their business or any material change in its accounting practices or methods, cash management practices or method of purchase, sale, lease, management, marketing, or operation;

(xii)       taken or omitted to take any action which could be reasonably anticipated to have a Material Adverse Effect;

(xiii)       made, changed or rescinded any Tax election, settled or compromised any Tax liability, amended any Tax Return or took any position on any Tax Return, took any action, omitted to take any action or entered into any other transaction that would have the effect of materially increasing the Tax liability or materially reducing any Tax assets of the Company in respect of any taxable period ending after the Closing Date;

                (xiv)      collected its accounts receivable or paid any accrued liabilities or accounts payable or prepaid any expenses or other items, in each case other than in the Ordinary Course of Business;

(xv)       entered into any transaction with any Affiliate; and

(xvi)       agreed or committed to any of the foregoing.

(c)       All notes and accounts receivable reflected on the Most Recent Financial Statements, and all accounts receivable of the Company and its Subsidiaries and the Business generated since the Most Recent Fiscal Month End (the “Receivables”), constitute bona fide receivables resulting from the sale of inventory, services or other obligations in favor of the Company and its Subsidiaries as to which full performance has been fully rendered, and are valid and enforceable claims. The Receivables are not subject to any pending, or to the Company’s Knowledge threatened, defense, counterclaim, right of offset, returns, allowances or credits, except to the extent reserved in the final calculation of Working Capital.

(d)       Except as otherwise set forth in Section 3.7(d) of the Disclosure Schedule, all accounts payable of the Company and its Subsidiaries have either been paid when due, are not yet due and payable in the Ordinary Course of Business, or are being contested by the Company and its Subsidiaries in good faith.     

(e)       The inventory of the Company and its Subsidiaries includes only items sold by the Company and its Subsidiaries in the Ordinary Course of Business. The inventory disposed of subsequent to the date of the Most Recent Fiscal Year End has been disposed of only in the Ordinary Course of Business.

3.8        Undisclosed Liabilities. The Company and its Subsidiaries do not have any, and to the Company’s Knowledge there is no basis for any, liability (whether known or unknown, whether asserted or unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, and whether due or to become due), except for liabilities that (a) are accrued or reserved against in the Most Recent Financial Statements, (b) were incurred subsequent to the Most Recent Fiscal Month End in the Ordinary Course of Business, (c) result from the obligations of the Company under this Agreement or the Ancillary Agreements, or (d) liabilities and obligations pursuant to any Contract listed on Section 3.13 of the Disclosure Schedule or not required by the terms of Section 3.13 to be listed on Section 3.13 of the Disclosure Schedule, in either case which arose in the Ordinary Course of Business and did not result from any default, tort, breach of contract or breach of warranty.

-16-


3.9       Legal Compliance.

(a)       The Business and the Company and its Subsidiaries (and with respect to the South Korean Sub, to the Company’s Knowledge), and their respective predecessors and Affiliates, have complied and are currently in compliance with all applicable Laws and Orders in all material respects as such relate to the Business, and no Proceeding has been filed or commenced or, to the Knowledge of the Company, threatened alleging any failure so to comply. Except as otherwise set forth in Section 3.9 of the Disclosure Schedule, since January 1, 2014, Orgenesis Parent, the Company and their Subsidiaries have not received any notice or communication alleging any non-compliance of the foregoing.

(b)       Section 3.9(b) of the Disclosure Schedule sets forth a correct and complete list of all Permits held by the Company and its Subsidiaries. Such Permits (i) constitute all material Permits necessary for the operation of the Business and (ii) are in full force and effect. No Proceeding is pending or, to the Knowledge of the Company, threatened to revoke or limit any Permit.

(c)       Neither the Business, nor the Company, nor any of its Subsidiaries, nor any of their officers, managers, equityholders, directors, agents, employees or any other Persons acting on their behalf has (i) violated the U.S. Foreign Corrupt Practices Act or any other applicable anti-bribery or anti-corruption Law, (ii) authorized or made any illegal payment or provided any unlawful compensation or gifts to any officer, employee or agent of any Governmental Body, or any employee, customer or supplier of the Business or the Company or any of its Subsidiaries, or (iii) accepted or received any unlawful contributions, payments, expenditures or gifts; and no Proceeding has been filed or commenced alleging any such contributions, payments, expenditures or gifts.

3.10       Tax Matters.

(a)       The Business and the Company and its Subsidiaries have filed with the appropriate taxing authorities all income and other material Tax Returns that they were required to file. All such Tax Returns are correct and complete in all material respects. All Taxes due and owing by the Business and the Company and its Subsidiaries (whether or not shown on any Tax Return) have been paid. The Company and its Subsidiaries are not currently the beneficiary of any extension of time within which to file any Tax Return or pay any Tax. There are no Liens for Taxes (other than Taxes not yet due and payable) upon the Business or the Company Securities or any of the assets of the Company or any of its Subsidiaries.

-17-


(b)       The accrual for Taxes on the Most Recent Balance Sheet, as adjusted for the passage of time through the Closing Date in accordance with past practice, would be adequate to pay all unpaid Taxes of the Company and its Subsidiaries through the Closing Date.

(c)       No material deficiency or proposed adjustment for any amount of Tax has been proposed, asserted or assessed by any taxing authority against the Business or the Company and its Subsidiaries that has not been paid, settled or otherwise resolved. There is no Proceeding or audit now pending, proposed or, to the Knowledge of the Company, threatened against the Company or any of its Subsidiaries or concerning the Company or any of its Subsidiaries with respect to any Taxes. The Business, the Company and its Subsidiaries have not been notified by any taxing authority that any issues have been raised with respect to any Tax Return. There has not been, within the past five (5) calendar years, an examination or written notice of potential examination of the Tax Returns filed with respect to the Business or the Company or any of its Subsidiaries by any taxing authority.

(d)      All income and other material Taxes that are required to be withheld or collected by the Business, the Company and its Subsidiaries, including, but not limited to, Taxes arising as a result of payments (or amounts allocable) to foreign persons or to employees, agents, contractors or equityholders of the Company or any of its Subsidiaries, have been duly withheld and collected and, to the extent required, have been properly paid or deposited as required by applicable Laws.

(e)       No claim has ever been made by any taxing authority in a jurisdiction where the Business, the Company or any of its Subsidiaries do not file Tax Returns that they are or may be subject to taxation by that jurisdiction.

(f)       Neither the Company nor any of its Subsidiaries is a “United States real property holding corporation” within the meaning of Section 897(c)(2) of the Code.

(g)       The Business has not waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect to the payment of any Tax or any Tax assessment or deficiency.

(h)       Neither the Company nor any of its Subsidiaries is a party to any “reportable transaction,” as defined in Treasury Regulation Section 1.6011 -4(b), and none of the Business, the Company or any of its Subsidiaries has been a party to such a transaction nor has claimed any Tax benefit from any such transaction in any taxable year which remains open to or for assessment.

(i)       None of the Business, the Company or any of its Subsidiaries (i) has been a member of an affiliated group filing a consolidated federal income Tax Return (other than a group the common parent of which was the Company or Orgenesis Parent) or (ii) has any liability for the Taxes of any Person (other than any of the Company or its Subsidiaries) under Treasury Regulation Section 1.1502 -6 (or any similar provision of state, local or foreign Law), as a transferee or successor, by Contract, or otherwise.

(j)       None of the Business, the Company or any of its Subsidiaries has engaged in a trade or business, had a permanent establishment (within the meaning of an applicable Tax treaty or convention between the United States and such foreign country), or otherwise been subject to taxation in any country other than the country of its formation.

-18-


(k)       None of the Business, the Company or any of its Subsidiaries is or has been a party to a transaction or Contract that is in conflict with the Tax Laws related to transfer pricing in any relevant jurisdiction. All applicable transfer pricing Laws have been complied with by the Business, the Company and its Subsidiaries, and all documentation required by all relevant transfer pricing Laws have been timely prepared and, if necessary, retained.

(l)       Section 3.10(l) of the Disclosure Schedule lists the United States federal tax classification of each Subsidiary of the Company.

3.11       Real Property.

(a)       The Business and the Company and its Subsidiaries do not own, and have never owned, any real property.

(b)       Section 3.11(b) of the Disclosure Schedule sets forth the address of each parcel of Leased Real Property, and a true and complete list of all Leases for each parcel of Leased Real Property.

(c)       Subject to the respective terms and conditions in the Leases, the Company or one of its Subsidiaries is the sole legal and equitable owner of the leasehold interest in the Leased Real Property and possesses good and marketable, indefeasible title thereto, free and clear of all Liens (other than Permitted Liens).

(d)       With respect to each parcel of Leased Real Property: (i) there are no pending or, to the Knowledge of the Company, threatened condemnation Proceedings, suits or administrative actions relating to any such parcel or other matters affecting adversely the current use, occupancy or value thereof; (ii) the ownership and operation of the Leased Real Property in the manner in which it is now owned and operated comply with all zoning, building, use, safety or other similar Laws in all material respects; (iii) all Improvements on any such parcel are in good operating condition, ordinary wear and tear excepted, are supplied with utilities and other services necessary for the operation of the Business as currently conducted at such facilities and safe for their current occupancy and use; (iv) neither the Company, nor any of its Subsidiaries nor Orgenesis Parent has received any notice of any special Tax, levy or assessment for benefits or betterments that affect any parcel of Leased Real Property and, to the Knowledge of the Company, no such special Taxes, levies or assessments are pending or contemplated; (v) there are no Contracts granting to any third party or parties the right of use or occupancy of any such parcel, and there are no third parties (other than the Company and its Subsidiaries) in possession of any such parcel except for such Contracts relating to Orgenesis Parent and/or its Subsidiaries that are set forth on Section 3.11(d) of the Disclosure Schedule; and (vi) each such parcel has adequate vehicular access to a road and there is no pending or, to the Knowledge of the Company, threatened termination of such access. The Leased Real Property comprises all of the real property used or intended to be used in the Business, and neither the Company nor any of its Subsidiaries is a party to any Contract, option or right of first refusal to purchase any real property or any portion thereof or interest therein.

-19-


3.12       Intellectual Property.

(a)       The Company and its Subsidiaries own and possess or have the right to use pursuant to a valid and enforceable written Contract, all Intellectual Property used in or necessary for the operation of the Business free and clear of all Liens.

(b)       To the Company’s Knowledge, the operation of the Business and the Company and its Subsidiaries (and the Business’s and the Company’s and its Subsidiaries’ products, services and methods of operation) have not infringed upon, misappropriated, or violated any Intellectual Property rights of third parties in any respect, and none of Orgenesis Parent, the Company, nor any of their Subsidiaries, nor any of their directors, managers and officers, has received any charge, complaint, claim, demand, or notice alleging any such infringement, misappropriation, or violation (including any claim that the Business or the Company or any of its Subsidiaries must license or refrain from using any Intellectual Property rights of any third party). No third party has challenged, infringed upon, misappropriated, or violated any Intellectual Property rights of the Business or the Company or its Subsidiaries. Section 3.12(b) of the Disclosure Schedule sets forth an accurate list and description of any charge, complaint, claim, demand or notice made by the Business, the Company or any of its Subsidiaries since January 1, 2015 alleging that a third party has interfered with, challenged, infringed upon, misappropriated, or violated any Intellectual Property rights of the Business, the Company or its Subsidiaries.

(c)       Sections 3.12(c)(i)-(iii) of the Disclosure Schedule identify the following Intellectual Property that is owned by the Company or any of its Subsidiaries or currently used in the conduct of the Business, whether registered or unregistered: (i) issued patents and patent applications, and counterparts claiming priority therefrom, and all related continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof (together, the “Patents”); (ii) trademarks, service marks, certification marks, collective marks, logos, slogans, trade dress, trade names (including social media user account names), and other source or business identifiers (together, the “Trademarks”); and (iii) works of authorship and other copyrightable subject matter, whether or not published, including copyrights, software code, and databases (and all translations, derivative works, adaptations, compilations, and combinations of the foregoing) (together, the “Copyrights”). Section 3.12(c)(iv) of the Disclosure Schedule identifies all internet domain names owned by the Company and its Subsidiaries. Section 3.12(c)(v) of the Disclosure Schedule identifies each license, sublicense, agreement, or other permission pursuant to which the Business, the Company or any of its Subsidiaries have granted any rights to any third party with respect to any of its Intellectual Property (together with any exceptions). The Company and its Subsidiaries have all right, title and interest in and to, free and clear of any Lien, license, or other restriction or limitation regarding use, and have the sole and exclusive right to use all the Intellectual Property required to be disclosed on Sections 3.12(c)(i)-(iv) of the Disclosure Schedule (the “Designated Intellectual Property”) (subject to the applicable license agreements listed in Section 3.12(c)(v) of the Disclosure Schedule), and such Intellectual Property is not subject to any outstanding Order restricting the use or licensing thereof by the Company or any of its Subsidiaries, and the Business, the Company and its Subsidiaries have not received any written claim challenging the validity or effectiveness of such Intellectual Property, and such Intellectual Property is valid and enforceable.

-20-


(d)       The Business, the Company (or its Subsidiaries to the extent applicable) have made all necessary filings and paid all necessary registration, maintenance and renewal fees to maintain the Designated Intellectual Property.

(e)       Each item of Intellectual Property owned or used by the Business, except for Customer Intellectual Property (which, for the purposes hereof, shall include any Intellectual Property of Orgenesis Parent or its Subsidiaries as a Customer) the Company and its Subsidiaries immediately prior to the Closing will be owned or available for use, respectively, by the Company and its Subsidiaries immediately subsequent to the Closing on identical terms and conditions as owned or used by the Business, the Company and its Subsidiaries immediately prior to the Closing.

(f)       Section 3.12(f) of the Disclosure Schedule identifies all third party Software used by the Company and its Subsidiaries in the operation of the Business (except for “off-the-shelf,” commercially-available software). The Business has not owned or used, and the Company and its Subsidiaries do not own or use, any Software developed by or for the Business, the Company or its Subsidiaries. The Company and its Subsidiaries have the right to use pursuant to a valid and enforceable written Contract, all Software used by in the operation of the Business.

(g)       All Intellectual Property owned by the Company and its Subsidiaries was developed by (i) employees of the Business, the Company or its Subsidiaries within the scope of their employment; or (ii) independent contractors who have entered into written agreements with the Business, the Company or one of its Subsidiaries that assigned all right, title and interest in and to any Intellectual Property developed to the Company or one of its Subsidiaries and whereby the ownership of such Intellectual Property vested immediately in the Company and its Subsidiaries (and to the extent that such vesting did not occur, the independent contractor is required to assign all such ownership to the Company and its Subsidiaries without further consideration). Except as set forth in Section 3.12(g) of the Disclosure Schedule, no employee or independent contractor of the Business, the Company or any of its Subsidiaries has entered into any agreement, contract, obligation, promise or undertaking (whether written or oral and whether express or implied) that restricts or limits in any way the scope of the Intellectual Property owned by the Company and its Subsidiaries or requires the employee or independent contractor to transfer, assign or disclose information concerning the Intellectual Property owned by the Company and its Subsidiaries to anyone other than the Company and its Subsidiaries.

(h)      Section 3.12(h) of the Disclosure Schedule contains a complete and accurate list of all rights in internet domain names, user names, handles and social media site names presently used or owned by the Company or its Subsidiaries or otherwise used in connection with the Business. The Company or its Subsidiaries own or have the right to use all such internet domain names, subdomains, URLs, website names, social media site names, user names, handles, email addresses, log-in names, passwords, pin numbers, customer numbers, and the like, or other account information necessary to access, transfer, use and update all of the foregoing presently used or owned by the Company or its Subsidiaries (collectively “Net Names”). All Net Names have been registered in the name of the Company or its Subsidiaries and are, and have been, in compliance with all Laws. No Net Name has been or is now involved in any dispute, opposition, invalidation or cancellation Proceeding and, to the Company’s Knowledge, no such action is threatened with respect to any Net Name. In addition, to the Knowledge of the Company and its Subsidiaries: (i) no Net Name has been challenged, interfered with or threatened in any way and (ii) no Net Name infringes, interferes with or is alleged to interfere with or infringe the trademark, copyright or domain name of any other Person.

-21-


(i)       The Company and its Subsidiaries have taken all necessary and reasonable steps to protect and preserve the confidentiality of all trade secrets, know-how, source code, databases, customer lists, schematics, ideas, algorithms and processes and all use, disclosure or appropriation thereof by or to any Person has been pursuant to the terms of a written agreement between such third party and the Company and its Subsidiaries. The Company and its Subsidiaries have complied with all of its confidentiality obligations under each Contract to which the Company and its Subsidiaries are a party.

3.13       Contracts.

(a)       Section 3.13(a) of the Disclosure Schedule lists the following Contracts to which the Company or any of its Subsidiaries is a party:

(i)       each Contract with any Material Customer or Material Vendor;

(ii)       each lease, rental or occupancy agreement, license, installment and conditional sale agreement, and other Contract affecting the ownership of, leasing of, title to, use of, or any leasehold or other interest in, any real or personal property;

(iii)       each joint venture, partnership or Contract involving a sharing of profits, losses, costs or liabilities with any other Person;

(iv)       each Contract relating to the acquisition, sale, transfer or disposition by the Company or any of its Subsidiaries of any material assets or properties, or of the operating business or the capital stock of or other equity interests in any other Person;

(v)       each Contract that contains provisions granting any rights of first refusal, rights of first negotiation, rights of exclusivity, most favored nations or similar rights to any Person;

(vi)       each Contract for the purchase, sale or license of any assets of the Company or any of its Subsidiaries, other than in the Ordinary Course of Business, and each Contract granting an option or preferential rights to purchase, sell or license any assets of the Company or any of its Subsidiaries;

(vii)       each Contract in which a Governmental Body is a counterparty;

(viii)       each Contract containing any covenant that purports to restrict the business activity of the Company or any of its Subsidiaries or limit the freedom of the Company or any of its Subsidiaries to engage in any line of business or to compete with any Person;

-22-


(ix)       each Contract for or relating to, or evidencing or guaranteeing, Debt;

(x)       each Contract providing for the payment of any cash or other compensation or benefits in connection with the Transactions;

(xi)       each Contract with any labor union or labor organization or any bonus, pension, profit sharing, retirement or any other form of deferred compensation plan or practice, whether formal or informal, or any severance agreement or arrangement;

(xii)       each Contract under which the Company or any of its Subsidiaries has advanced or loaned any amounts to any Person;

(xiii)       each franchise, dealership, vendor, manufacturing or service center agreements;

(xiv)       each Contract with Orgenesis Parent or any Affiliate of the Company, any of its Subsidiaries, or Orgenesis Parent;

(xv)       any settlement or similar agreement;

(xvi)      each employment or consulting Contract or other Contract with any of their officers, managers, partners, directors, employees, agents or representatives;

(xvii)       each Intellectual Property Agreement;

(xviii)       each confidentiality agreement and non-disclosure agreement still in effect;

(xix)       each Contract which purports to be binding on Affiliates of the Company (other than the Company’s Subsidiaries); and

(xx)       any other agreement material to the Company or any of its Subsidiaries whether or not entered into in the Ordinary Course of Business.

(b)       The Company has delivered to Investor a correct and complete copy of each written Material Contract, together with all amendments, exhibits, attachments, waivers or other changes thereto. Section 3.13(b) of the Disclosure Schedule contains an accurate and complete description of all material terms of all oral Material Contracts (if any).

(c)       Each Material Contract is legal, valid, binding, enforceable, in full force and effect and will continue to be legal, valid, binding and enforceable on identical terms following the Closing Date. Except as specifically disclosed and described in Section 3.13(c) of the Disclosure Schedule, (i) no Material Contract has been breached or cancelled by the Company, any of its Subsidiaries or, to the Knowledge of the Company, any other party thereto, (ii) the Company or each of its Subsidiaries has materially performed all obligations under such Material Contracts required to be materially performed by the Company or such Subsidiary, (iii) there is no event which, upon giving of notice or lapse of time or both, would constitute a breach or default under any such Material Contract by the Company or any of its Subsidiaries, or to the Company’s Knowledge, by any other party, or would permit the termination, modification or acceleration of such Material Contract, (iv) no party has given notice of breach, default, termination or non-renewal of any Material Contract, and (v) neither the Company nor any of its Subsidiaries has assigned, delegated or otherwise transferred to any Person any of its rights, title or interest under any such Material Contract.

-23-


(d)       Section 3.13(d) of the Disclosure Schedule sets forth each Contract to which Orgenesis Parent or any of its Subsidiaries is a party that is used in the operation of the Business or was used in the operation of the Business any time during the twelve (12) months prior to Closing.     

3.14       Insurance. Section 3.14(a) of the Disclosure Schedule sets forth the following information with respect to each insurance policy (including policies providing property, casualty, liability, director & officer, and workers’ compensation coverage and bond and surety arrangements) with respect to which the Company or any of its Subsidiaries is a party, a named insured, or otherwise the beneficiary of coverage (collectively, the “Company Insurance Agreements”): (a) the name of the insurer, the name of the policyholder, and the name of each covered insured; (b) the policy number and the period of coverage; and (c) a description of any retroactive premium adjustments or other material loss-sharing arrangements.

There is no claim by the Company or any of its Subsidiaries or any other Person pending under any such policies and bonds related to the Business as to which coverage has been questioned, denied or disputed. All premiums payable under all such policies and bonds have been paid. To the Company’s Knowledge, there are no threatened terminations of, or material premium increases with respect to, any of such policies or bonds. Section 3.14(b) of the Disclosure Schedule sets forth a list of all claims made under the Company Insurance Agreements, or under any other insurance policy, bond or agreement covering the Business, the Company or any of its Subsidiaries or their operations since January 1, 2014. Except as otherwise set forth in Section 3.14(b) of the Disclosure Schedule, since January 1, 2014, the Business, the Company and its Subsidiaries have maintained insurance policies with coverage and policy limits that are substantially similar to the coverage and policy limits provided by the Company Insurance Agreements.

3.15       Litigation. Except as set forth in Section 3.15(a) of the Disclosure Schedule, there are no (and during the last four (4) years preceding the date hereof, there have not been any) complaints, charges, Proceedings, Orders, or investigations pending or, to the Knowledge of the Company, threatened or anticipated relating to or affecting the Business, the Company or any of its Subsidiaries. There is no outstanding Order to which the Business, the Company or any of its Subsidiaries is subject. Section 3.15(b) of the Disclosure Schedule sets forth an accurate list and description of all Proceedings that the Company or any of its Subsidiaries or Orgenesis Parent or its Affiliates (to the extent related to the Company or its Subsidiaries or the Business) has initiated or threatened in writing to initiate since January 1, 2014.

-24-


3.16       Employees.

(a)       Section 3.16(a)(i) of the Disclosure Schedule sets forth a complete and correct list of all officers, employees and consultants of the Company and its Subsidiaries, showing for each: (i) name, (ii) hire date, (iii) current job title, (iv) actual base salary, bonus, commission or other remuneration paid during 2017, (v) 2018 base salary level and 2018 target bonus, and (vi) indicating whether there has been any increase in compensation, bonus, incentive, or service award or any grant of any severance or termination pay or any other increase in benefits or any commitment to do any of the foregoing since January 1, 2017. Section 3.16(a)(ii) of the Disclosure Schedule sets forth a complete and correct list of all employees or contractors of Orgenesis Parent or any of its Subsidiaries who, any time during the twelve (12) months prior to Closing, were utilized in the operation of the Business or spent a material amount of time working on matters related to, or providing material services in, the operation of the Business.

(b)       The Company has provided Investor with access to complete and correct copies of all trade secret, non-compete, non-disclosure and invention assignment agreements, and all manuals and handbooks applicable to any current or former director, manager, officer, employee or consultant of the Company or any of its Subsidiaries. The employment or consulting arrangement of each officer, employee or consultant of the Company and its Subsidiaries is, subject to applicable Laws involving the wrongful termination of employees and consultants, terminable at will (without the imposition of penalties or damages) by the Company or its Subsidiaries as the case may be, and neither the Company nor any of its Subsidiaries has any severance obligations if any such officer, employee or consultant is terminated. To the Knowledge of the Company, no officer, employee or consultant of the Company or any of its Subsidiaries or any group of officers, employees or consultants of the Company or any of its Subsidiaries has any plans to terminate its employment or consulting arrangement with the Company or any of its Subsidiaries.

(c)       Neither the Business, nor the Company nor any of its Subsidiaries has experienced (nor, to the Knowledge of the Company, has it been threatened with) any strike, slow down, work stoppage or material grievance, claim of unfair labor practices, or other collective bargaining dispute within the past three (3) years. Neither the Business, nor the Company nor any of its Subsidiaries has committed any material unfair labor practice. The Company has no Knowledge of any organizational effort presently being made or threatened by or on behalf of any labor union with respect to employees of the Company or its Subsidiaries. The Business and the Company and each of its Subsidiaries have paid in full to all of its employees and independent contractors all wages, salaries, commissions, bonuses, benefits and other compensation due and payable to such employees and independent contractors.

3.17       Employee Benefits.

(a)       Section 3.17 of the Disclosure Schedule lists each Employee Benefit Plan that the Company or any of its Subsidiaries maintains or to which the Company or any of its Subsidiaries contributes or has any obligation to contribute or with respect to which the Company and its Subsidiaries have any liabilities.

-25-


(i)       Each such Employee Benefit Plan (and each related trust, insurance Contract, or fund, if any) has been maintained, funded and administered in accordance with the terms of such Employee Benefit Plan and complies in form and in operation in all respects with applicable Laws.

(ii)       All required reports and descriptions have been timely filed and/or distributed in accordance with the applicable Laws with respect to each such Employee Benefit Plan. The requirements of applicable Laws have been met in all material respects with respect to each such Employee Benefit Plan.

(iii)       All contributions (including all employer contributions and employee salary reduction contributions) that are due have been made within the time periods prescribed by applicable Laws to each applicable Employee Benefit Plan. All premiums or other payments for all periods ending on or before the Closing Date have been paid with respect to each such Employee Benefit Plan.

(iv)       The Business, the Company and its Subsidiaries do not have any Employee Benefit Plans subject to the Laws of the United States.

(v)      There have been no prohibited transactions with respect to any such Employee Benefit Plan and no fiduciary with respect to any such Employee Benefit Plan has any liability for material breach of fiduciary duty or any other failure to act or comply in connection with the administration or investment of the assets of any such Employee Benefit Plan. No Proceeding with respect to the administration or the investment of the assets of any such Employee Benefit Plan (other than routine claims for benefits) is pending or, to the Knowledge of the Company, threatened.

(vi)       The Company has made available to Investor correct and complete copies of the plan documents and summary plan descriptions, the most recent annual reports, and all related trust agreements, insurance Contracts, and other funding arrangements which implement each such Employee Benefit Plan.

3.18       Debt. Except as set forth on Section 3.18 of the Disclosure Schedule, the Company and its Subsidiaries do not have any Debt and are not liable for any Debt of any other Person.

3.19       Environmental, Health, and Safety Matters.

(a)       The Business, the Company and its Subsidiaries have complied and are in compliance with all Environmental, Health, and Safety Requirements.

(b)       Without limiting the generality of the foregoing, the Business, the Company and its Subsidiaries have obtained, have complied, and are in compliance with all Permits and other authorizations that are required pursuant to Environmental, Health, and Safety Requirements for the occupation of the facilities of the Company and its Subsidiaries and the operation of the Business. A list of all such Permits and other authorizations is set forth on Section 3.19(b) of the Disclosure Schedule.

-26-


(c)       Neither the Business, the Company nor any of its Subsidiaries has received any written or oral notice, report or other information regarding any actual or alleged violation of Environmental, Health, and Safety Requirements, or any liabilities or potential liabilities (whether accrued, absolute, contingent, unliquidated or otherwise), including any investigatory, remedial or corrective obligations, relating to any of them, their current or former facilities or the Leased Real Property arising under Environmental, Health, and Safety Requirements.

(d)       Except as set forth on Section 3.19(d) of the Disclosure Schedule, no property or facility owned, leased or operated by the Company or its Subsidiaries contains any underground storage tanks currently, nor, to the Knowledge of the Company, has contained any underground storage tanks in the past.

(e)       Neither the Business, the Company nor any of its Subsidiaries has treated, stored, disposed of, arranged for or permitted the disposal of, transported, handled, or released any substance, including without limitation any Hazardous Substance, or owned or operated any property or facility (and no such property or facility is contaminated by any such substance) in a manner that has given or would give rise to material liabilities, including any material liability for investigation costs, response costs, remedial costs, corrective action costs, personal injury, property damage, natural resources damages or attorney and consultant fees and costs, pursuant to any Environmental, Health, and Safety Requirements or any other applicable Law.

(f)       There are no environmental conditions or circumstances on the Leased Real Property that pose an unreasonable risk to the environment or the health or safety of Persons or Hazardous Substances present at, on or under the Leased Real Property in violation of Environmental, Health, and Safety Requirements.

(g)       Neither this Agreement nor the consummation of the Transactions will result in any obligations for site investigation or cleanup, or notification to or Consent of Governmental Bodies or third parties, pursuant to any of the Environmental, Health, and Safety Requirements.

(h)       Section 3.19(h) of the Disclosure Schedule lists each written environmental audit, health and safety audit, Phase I environmental site assessment, Phase II environmental site assessment or investigation, soil and/or groundwater report, environmental compliance assessment prepared within the past five (5) years by the Business, the Company or any of its Subsidiaries or, to the Knowledge of the Company, any Governmental Body under the Environmental, Health, and Safety Requirements relating to any property currently or formerly owned or operated by the Business, the Company or any of its Subsidiaries or their Affiliates.

3.20       Business Continuity. Except as set forth in Section 3.20 of the Disclosure Schedule, none of the Software, computer hardware (whether general or special purpose), telecommunications capabilities (including all voice, data and video networks), data storage and other similar or related items of automated, computerized, and/or software systems and any other networks or systems and related services that are used by or relied on by the Business, the Company or its Subsidiaries in the conduct of the Business (collectively, the “Systems”) have experienced bugs, failures, breakdowns, breaches, unauthorized access, or continued substandard performance in the past two (2) years that has caused or reasonably could be expected to cause any substantial disruption or interruption in or to the use of any such Systems by the Business, the Company or its Subsidiaries.

-27-


3.21       Certain Business Relationships with the Company and its Subsidiaries.

(a)       Except as set forth on Section 3.21 of the Disclosure Schedule, none of Orgenesis Parent or its Subsidiaries, nor to the Knowledge of Orgenesis Parent, any officer, or director of Orgenesis Parent, the Company or any of their Subsidiaries, or any Affiliates of any of the foregoing (other than the Company and its Subsidiaries):

(i)       owns, directly or indirectly, any stock, equity or other ownership interest or investment in any Person that is engaged in the Business or is a competitor, supplier, customer, lessor or lessee of the Company or any of its Subsidiaries; provided, however, that the foregoing representation shall be deemed not to be made as to the ownership of not more than two percent (2%) of the capital stock of any such Person that has securities registered pursuant to Section 13 or Section 15 of the Securities Exchange Act;

(ii)       has any claim against or owes any amount to, or is owed any amount by, the Company or any of its Subsidiaries;

(iii)       has any interest in or owns any assets, properties or rights used in the conduct of the Business;

(iv)       is a party to any Contract to which the Company or any of its Subsidiaries is a party or which otherwise benefits the Business; or

(v)       has received from or furnished to the Company or any of its Subsidiaries any goods or services since the Most Recent Fiscal Year End, or is involved in any business relationship (other than an employment relationship in the Ordinary Course of Business) with the Company or any of its Subsidiaries.

(b)       Without derogating from Section 4.8, the Company and its Subsidiaries do not have any liability, and there is no basis for any liability, nor is Orgenesis Parent aware of any claim, arising out of or related to that certain manufacturing services agreement, by and between Orgenesis Parent and MaSTherCell S.A. (the “Orgenesis Manufacturing Agreement”), other than liabilities and obligations for performance pursuant to the terms of the Orgenesis Manufacturing Agreement and that did not result from any default or breach of the terms of the Orgenesis Manufacturing Agreement.

3.22       Customers and Vendors.

(a)       Section 3.22 of the Disclosure Schedule sets forth a correct and complete list of the twenty-five (25) largest suppliers and vendors (by dollar volume) of products or services to the Company and its Subsidiaries with respect to the Business (the “Material Vendors”), and all customers of the Company and its Subsidiaries with respect to the Business (the “Material Customers”), each during the calendar year 2016, the calendar year 2017, and the five (5) months ended May 31, 2018. Section 3.22 of the Disclosure Schedule also sets forth, for each such Material Vendor and Material Customer, the aggregate payments from and to such Person by the Company and its Subsidiaries during such periods. There are no outstanding disputes with any of such Material Vendors or Material Customers.

-28-


(b)       Since January 1, 2017, none of the Material Vendors have indicated that it shall stop, or materially decrease the rate of, or materially change the pricing of, supplying materials, products or services to the Company or its Subsidiaries, or otherwise materially change the terms of its relationship with the Company or its Subsidiaries. Neither the Company, nor any of its Subsidiaries has any reason to believe that any Material Vendor will stop, or materially decrease the rate of, or materially change the pricing of, supplying products or services to the Company or its Subsidiaries or otherwise materially change the terms of its relationship with the Company or its Subsidiaries after, or as a result of, the consummation of any Transactions. Neither the Company, nor any of its Subsidiaries know of any fact, condition or event which would adversely affect the relationship of the Company or its Subsidiaries with any such Material Vendor.

(c)       Since January 1, 2017, none of the Material Customers have indicated that it shall stop, or materially decrease the rate of, or materially change the pricing of, buying products or services from the Company or its Subsidiaries or otherwise materially change the terms of its relationship with the Company or its Subsidiaries. Neither the Company, nor any of its Subsidiaries, has any reason to believe that any Material Customer will stop, or materially decrease the rate of, of materially change the pricing of, buying products or services from the Company or its Subsidiaries or otherwise materially change the terms of its relationship with the Company or its Subsidiaries after, or as a result of, the consummation of any Transactions. Neither the Company, nor any of its Subsidiaries, know of any fact, condition or event which would adversely affect the relationship of the Company or its Subsidiaries with any such Material Customer.

3.23       Product Warranty. Section 3.23 of the Disclosure Schedule sets forth an accurate, correct and complete list and summary description of all claims arising from any product or service, alleged to have been manufactured, sold, provided, distributed, leased, or delivered by the Business, the Company and its Subsidiaries not in conformity with all applicable contractual commitments and all express and implied warranties during the prior three (3) years.

3.24       Product Liability. Section 3.24 of the Disclosure Schedule sets forth an accurate, correct and complete list and summary description of all claims arising from or alleged to arise from any injury to person or property as a result of the ownership, possession or use of any product manufactured, processed, sold, provided, distributed or delivered by the Business, the Company, its Subsidiaries or their predecessors during the prior three (3) years. Neither the Company nor any of its Subsidiaries has any liability (and to the Company’s Knowledge there is no reasonable basis for any present or future action, suit, proceeding, hearing, investigation, charge, complaint, claim, or demand against the Company or any of its Subsidiaries giving rise to any liability) arising out of any injury to individuals or property as a result of the ownership, possession, or use of any product manufactured, processed, sold, provided, distributed or delivered by the Business, the Company, its Subsidiaries or any of their predecessors.

-29-


3.25       Information Privacy and Data Security.

(a)       The Business’s, the Company’s and its Subsidiaries’ practices concerning the creation, receipt, maintenance, transmission, use, disclosure, processing, protection, collection, analysis, retention, storage, privacy, security, breach, transfer, destruction, and disposal of Personal Information comply with, and have not violated, any (i) Contract, (ii) Privacy Laws, or (iii) written policy or privacy statement of the Company or its Subsidiaries.

(b)       The Company and its Subsidiaries have implemented reasonable administrative, physical, contractual and technical safeguards sufficient to protect the Personal Information processed or maintained by the Company and its Subsidiaries, and such safeguards are sufficient for the size and scope of the Company and its Subsidiaries and the risks posed to the Personal Information processed by the Business, the Company and its Subsidiaries. The Company and its Subsidiaries maintain reasonable and sufficient written policies and procedures concerning the (i) protection of Personal Information, (ii) the protection of the systems, technology and networks that process such Personal Information, and (iii) prevention, detection, containment, and correction of security violations respecting its information systems.

(c)       Section 3.25(c) of the Disclosure Schedule sets forth all incidents impacting the confidentiality, security, integrity, or availability of the Business’s, the Company’s and its Subsidiaries’ information systems and/or the Personal Information processed by the Business, the Company and its Subsidiaries.

ARTICLE 4

POST-CLOSING COVENANTS

The Parties agree as follows with respect to the period following the Closing.

4.1       General. In case at any time after the Closing any further action is reasonably necessary to carry out the purposes of this Agreement, each of the Parties will take such further action (including the execution and delivery of such further instruments and documents) as any other Party reasonably may request, all at the sole cost and expense of the requesting Party (unless the requesting Party is entitled to indemnification therefor under Article 6). In furtherance of the foregoing, the Parties agree that each of the Parties will take such further action (including the execution and delivery of such further instruments and documents) as may be reasonably requested by the Investor in order to duly transfer any assets, properties or rights that are owned by Orgenesis Parent or any of its Subsidiaries that were not transferred to the Company or its Subsidiaries in connection with the Reorganization but that either (a) are necessary to operate the Business or (b) were used in the operation of the Business at any time during the twelve (12) month period prior to the Closing Date.

4.2       Litigation Support. In the event and for so long as any of Investor or the Company or its Subsidiaries is actively contesting or defending against any Proceeding in connection with any fact, situation, circumstance, status, condition, activity, practice, plan, occurrence, event, incident, action, failure to act, or transaction on or prior to the Closing Date involving the Company or any of its Subsidiaries, the Company will cooperate with it and its counsel in the contest or defense and provide such testimony and access to the Company’s books and records as shall be necessary in connection with the contest or defense (and Orgenesis Parent shall use commercially reasonable efforts to promptly review, respond to and, to the extent Orgenesis Parent is not prohibited by Law or by contractual obligation, comply with any reasonable requests for information and/or documents in connection therewith), all at the sole cost and expense of the Company (unless Investor is entitled to indemnification therefor under Article 6).

-30-


4.3       Transition. Orgenesis Parent shall not intentionally take any action that is designed or intended to have the effect of discouraging any lessor, licensor, Customer, supplier, or other business associate of the Company and its Subsidiaries from maintaining the same business relationships with the Company or its Subsidiaries after the Closing as it maintained with the Company and its Subsidiaries prior to the Closing.

4.4       Confidentiality. Orgenesis Parent agrees not to, directly or indirectly, disclose to any other Person or use any Confidential Information. If Orgenesis Parent is requested or required pursuant to written or oral question or request for information or documents in any Proceeding, interrogatory, subpoena, civil investigation demand or similar process to disclose any Confidential Information, then Orgenesis Parent will notify Investor and the Company promptly of the request or requirement so that Investor or the Company may seek an appropriate protective order or waive compliance with the provisions of this Section 4.4. If, in the absence of a protective order or the receipt of a waiver hereunder, Orgenesis Parent is, on the advice of counsel, compelled to disclose any Confidential Information to any tribunal or else stand liable for contempt, then Orgenesis Parent may disclose the Confidential Information to the tribunal; provided, however, that Orgenesis Parent shall use reasonable commercial efforts to obtain, at the request of Investor, an order or other assurance that confidential treatment will be accorded to such portion of the Confidential Information required to be disclosed as Investor shall designate. The foregoing provisions shall not apply to any Confidential Information that (i) is generally available to the public immediately prior to the time of disclosure unless such Confidential Information is so available due to the actions of Orgenesis Parent or (ii) that does not relate to the Company or its Subsidiaries, the Business or a Customer.

4.5       Covenant Not to Compete. Nothing in this Agreement shall derogate from, or limit, Orgenesis Parent from conducting any business as it presently conducts or may conduct in the future (including, without limitation, business related to the manufacturing, researching, marketing, developing, selling and commercialization (either alone or jointly with Third Parties) products that are not directly related to the Business); provided, however, that during the Restricted Period, Orgenesis Parent will not directly (whether on its, his or her own account, or as an owner, operator, manager, consultant, officer, director, employee, investor, independent contractor, agent, representative or otherwise), anywhere in the Applicable Area, conduct the Business. Any activities or transactions conducted by Orgenesis Parent with any Third Party which does not directly relate to Orgenesis Parent as a CDMO business shall not be deemed a violation of this Section 4.5.

4.6       Covenant Not to Solicit. During the Restricted Period, Orgenesis Parent will not, and will cause each of its Affiliates not to, in any manner (whether on its, his or her own account, or as an owner, operator, manager, consultant, officer, director, employee, investor, independent contractor, agent, representative or otherwise), (a) call upon, solicit or provide services to any Customer with the intent of selling or attempting to sell any products or services that are the same as, or competitive with, those offered by the Business, (b) hire or engage, or recruit, solicit or otherwise attempt to employ or engage, or enter into any business relationship with, any Person currently or formerly employed by, or providing consulting services to, the Company or any of its Subsidiaries, or induce or attempt to induce any Person to leave such employment or consulting arrangement, (c) in any way materially interfere with the relationship between the Company or any of its Subsidiaries and any employee, consultant, Customer, sales representative, broker, supplier, licensee or other business relation (or any prospective employee, consultant, customer, sales representative, broker, supplier, licensee or other business relation) of the Company or any of its Subsidiaries (including, without limitation, by making any negative or disparaging statements or communications regarding Investor, the Company, any of its Subsidiaries or any of their operations, officers, directors, managers, employees, Affiliates or investors), or (d) recommend, or provide any reference to a third party for, any employee or contractor of the Company or any of its Subsidiaries; provided, however that (i) Orgenesis Parent may recruit, hire or engage former employees and consultants to the Company and its Subsidiaries after such former employees or consultants have ceased to be employed or otherwise engaged by the Company or any of its Subsidiaries for a period of at least twelve (12) months, (ii) Orgenesis Parent may obtain the services of certain employees of the Company and its Subsidiaries pursuant to a services agreement between Orgenesis Parent and the Company and with the prior written approval of a Supermajority of the Board (as defined in the Stockholders’ Agreement), (iii) Orgenesis Parent may recruit, hire or engage Noam Bercovich, Moshe Cohen, Moran Hod, Dana Fuchs-Telem and Moshe Lindner, and (iv) nothing in this Section 4.6 will prohibit Orgenesis Parent from engaging in any activity that does not violate Section 4.5.

-31-


4.7       Enforcement. If the final judgment of a court of competent jurisdiction declares that any term or provision of Sections 4.4, 4.5 or 4.6 is invalid or unenforceable, then the Parties agree that the court making the determination of invalidity or unenforceability shall have the power to reduce the scope, duration or area of the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closer to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified after the expiration of the time within which the judgment may be appealed. In the event of litigation involving Sections 4.4, 4.5 or 4.6, the non-prevailing party shall reimburse the prevailing party for all reasonable costs and expenses actually incurred by the prevailing party, including reasonable attorneys’ fees and expenses, incurred in connection with any such litigation, including any appeal therefrom. The existence of any claim or cause of action by Orgenesis Parent against Investor, the Company or any of their respective Affiliates, whether predicated on this Agreement or otherwise, will not constitute a defense to the enforcement by Investor of the provisions of Sections 4.4, 4.5 or 4.6, which Sections will be enforceable notwithstanding the existence of any breach by Investor or the Company. Notwithstanding the foregoing, (a) Orgenesis Parent will not be prohibited from pursuing such claims or causes of action against Investor or the Company and (b) if Orgenesis Parent obtains a binding judgment against Investor which provides that Investor owes a Future Payment in accordance with the terms of this Agreement and Investor has not paid such Future Payment to the Company within thirty (30) days of the issuance of such judgment, then such non-payment of such Future Payment may constitute a defense to the enforcement by Investor of the provisions of Sections 4.4, 4.5 or 4.6.

-32-


4.8       Release. Orgenesis Parent, for itself and each of its Affiliates, and its and their heirs, personal representatives, successors and assigns (collectively, the “Releasors”), hereby (a) forever fully and irrevocably releases and discharges Investor, the Company, each of its respective Subsidiaries, and each of their respective predecessors, successors, wholly owned subsidiaries and present equityholders, members, managers, directors, officers, employees, contractors, and agents (collectively, the “Released Parties”) from any and all actions, suits, claims, demands, debts, agreements, obligations, promises, judgments, or liabilities of any kind whatsoever in law or equity and causes of action of every kind and nature, or otherwise (including, claims for damages, costs, expenses, and attorneys’, brokers’ and accountants fees and expenses) related to events, facts, conditions or circumstances existing or arising prior to the Closing Date, which the Releasors can, shall or may have against the Released Parties, whether known or unknown, suspected or unsuspected (collectively, the “Released Claims”), and (b) irrevocably agrees to refrain from directly or indirectly asserting any claim or demand or commencing (or causing to be commenced) any Proceeding against any Released Party based upon any Released Claim. Notwithstanding the preceding sentence of this Section 4.8, “Released Claims” does not include, and the provisions of this Section 4.8 shall not release or otherwise diminish, (x) the obligations of any Party set forth in or arising under any provisions of this Agreement or the Ancillary Agreements or breach thereof (including, without limitation, with respect to any Intellectual Property Rights), or (y) the rights and obligations of Orgenesis Parent and any of its Affiliates on the one hand, and the Company and any of its Subsidiaries on the other hand, set forth in or arising under any provisions of the Orgenesis Manufacturing Agreement, or (z) any claims against the Company, or any of its Subsidiaries that relate to Orgenesis Parent as a customer of the Business, or (aa) any claims that Orgenesis Parent may have against the Company or its Subsidiaries based upon fraud or willful or intentional misconduct; provided, however, that Orgenesis Parent shall indemnify the Investor for all Adverse Consequences that may be suffered by the Investor in connection with or as a result of any such claim. Nothing herein shall derogate from, or be deemed to limit, Orgenesis Parent’s ability to bring an action against the Company and/or the Company’s Subsidiaries in the event such action is required under Law as a necessary step for Orgenesis Parent to bring suit against any executive, director, stockholder (but not the Investor) or officer of the Company or its Subsidiaries, provided, however, that Orgenesis Parent shall indemnify Investor, the Company and its Subsidiaries for all Adverse Consequences that may be suffered by Investor, the Company or its Subsidiaries as a result of such action.

4.9       Israel Sub and South Korea Sub. Orgenesis Parent will, at its sole expense, take all actions necessary so that within twelve (12) months following the Closing, Orgenesis Parent has (a) acquired all equity and other ownership interests of both the Israel Sub and the South Korea Sub and (b) for no additional consideration contributed all right, title and interest in and to all such equity and other ownership interests, free and clear of all Liens, to the Company.     

4.10       Stockholders’ Agreement Terms. Orgenesis Parent shall use its best efforts to ensure that the Stockholders’ Agreement Terms are Properly Approved as soon as possible after Closing. If Orgenesis Parent obtains Proper Approval of the Stockholders’ Agreement Terms, then in the event that the applicable laws of the State of Nevada require Orgenesis Parent to obtain an additional or secondary approval of the Stockholders’ Agreement Terms from its shareholders, Investor shall have no recourse or remedy of any kind against Orgenesis Parent, the Company or any Subsidiary and shall not be entitled to any indemnification under this Agreement for any damages and or liability that Investor may incur as a result of such additional or secondary approval. The Investor hereby waives, and agrees not to bring any claims against, Orgenesis Parent, the Company or any of their Subsidiaries in the event that applicable laws require Orgenesis Parent to secure any such additional or second approval of the Stockholders’ Agreement Terms from its shareholders and that Orgenesis Parent, the Company and any of their Subsidiaries shall not have any liability of any kind, including breach of this Agreement or any Ancillary Agreement for any Adverse Consequences resulting from any such additional or second approval. The Investor hereby agrees and confirms that Orgenesis Parent shall have no obligation of any kind toward the Investor with respect to such secondary approval (including, without limitation, obtaining any proxies) beyond approaching its shareholders for such approval.

-33-


4.11       QMS License Agreement. As part of the Reorganization, Orgenesis Parent has assigned to the Company that certain License Agreement, by and between Orgenesis Parent and MaSTherCell S.A., dated December 30, 2016 (the “QMS License Agreement”), but Orgenesis Parent shall remain solely responsible for paying all costs and making all payments (including any in-kind contributions, which may be determined by Orgenesis Parent in its reasonable discretion so long as any such contributions comply with the terms of the QMS License Agreement) under or related to the QMS License Agreement as if Orgenesis Parent was still a party to the QMS License Agreement. The Board of Directors of the Company will provide reasonable assistance and support to Orgenesis Parent in connection with Orgenesis Parent’s structuring of any in-kind contributions to be made by Orgenesis Parent.

ARTICLE 5

CLOSING DELIVERIES

5.1       Closing Deliveries of Orgenesis Parent. At or prior to the Closing, the Company or Orgenesis Parent shall deliver to Investor:

(a)       duly executed certificates representing all of the Company Preferred Stock against payment of the Estimated Cash Payment;

(b)       all Consents and Permits of Governmental Bodies and other Persons necessary for the consummation of the Transactions, including those Consents and Permits set forth on Schedule 5.1(b);

(c)       a certificate of the Secretary of the Company, on behalf of the Company and each of its Subsidiaries, dated as of the Closing Date, attaching and certifying (i) the Organizational Documents of the Company and each of its Subsidiaries, (ii) the resolutions of the Company authorizing and approving the entry into and consummation of the Transactions, and (iii) the incumbency and signatures of the Persons signing this Agreement and the Ancillary Agreements to which the Company or any of its Subsidiaries is a party;

-34-


(d)       a certificate of the Secretary of Orgenesis Parent, dated as of the Closing Date, attaching and certifying (i) the Organizational Documents of Orgenesis Parent, (ii) the resolutions of Orgenesis Parent and each of its Subsidiaries (as necessary) authorizing and approving the entry into and consummation of the Transactions, and (iii) the incumbency and signatures of the Persons signing this Agreement and the Ancillary Agreements to which Orgenesis Parent or any of its Subsidiaries is a party;

(e)       good standing certificates for the Company and to the extent applicable, each of its Subsidiaries, from the jurisdiction of each such Person’s organization and each jurisdiction in which the Company or any of its Subsidiaries is qualified to do business;

(f)       counterpart signature pages to the Employment Agreement signed by the Company and Darren Head;

(g)       signed resignation letters from each member of the board of directors or board of managers or similar governing body and each officer of the Company and its Subsidiaries set forth on Schedule 5.1(g);

(h)       all documentation necessary to obtain releases of all Liens (other than the Permitted Liens) related to the Company and its Subsidiaries, including appropriate UCC termination statements;

(i)       payoff and release letters from the holders of the Debt set forth on Schedule 5.1(i) that (i) reflect the amounts required in order to pay in full such Debt and (ii) provide that, upon payment in full of the amounts indicated, all Liens with respect to the assets of the Company or any of its Subsidiaries shall be terminated and of no further force and effect, together with UCC-3 termination statements with respect to the financing statements filed against the assets or equity interests of the Company or any of its Subsidiaries by the holders of such Liens;

(j)       a counterpart signature page to the Stockholders’ Agreement signed by Orgenesis Parent;

(k)       counterpart signature pages to the Advisory Services Agreements signed by the Company;

(l)       a copy of the Amended and Restated Certificate of Incorporation of the Company filed with the Secretary of State of the State of Delaware;

(m)       all documentation necessary to terminate each related party Contract set forth on Schedule 5.1(m); and

(n)       all other instruments and documents required by this Agreement to be delivered by the Company, its Subsidiaries, or Orgenesis Parent to Investor, and such other instruments and documents which Investor or its counsel may reasonably request to effectuate the Transactions.

-35-


All such agreements, documents and other items shall be in form and substance satisfactory to Investor.

5.2       Closing Deliveries of Investor. At or prior to the Closing, Investor shall deliver to Orgenesis Parent:

(a)       a certificate from the Secretary of Investor, dated as of the Closing Date, attaching and certifying (i) the Organizational Documents of Investor, (ii) the resolutions of Investor authorizing and approving the entry into and consummation of the Transactions, and (iii) the incumbency and signatures of the Persons signing this Agreement and the Ancillary Agreements to which Investor is a party;

(b)       a counterpart signature page to the Stockholders’ Agreement signed by Investor;

(c)       counterpart signature pages to the Advisory Services Agreements signed by Great Point Partners, LLC and GPP Securities, LLC, as applicable; and

(d)       all other instruments and documents required by this Agreement to be delivered by Investor to the Company or Orgenesis Parent, and such other instruments and documents which Orgenesis Parent or its counsel may reasonably request to effectuate the Transactions.

All such agreements, documents and other items shall be in form and substance satisfactory to Orgenesis Parent.

ARTICLE 6

REMEDIES FOR BREACHES OF THIS AGREEMENT

6.1       Indemnification by Orgenesis Parent.

(a)       Subject to the terms and conditions of this Article 6, Orgenesis Parent will indemnify, defend and hold harmless Investor and the Company (the “Investor Indemnitees”) from and against the entirety of any Adverse Consequences that any Investor Indemnitee may suffer or incur (including any Adverse Consequences they may suffer or incur after the end of any applicable survival period, provided that an indemnification claim with respect to such Adverse Consequence is made pursuant to this Article 6 prior to the end of any applicable survival period) resulting from, arising out of, relating to, or caused by (i) any breach of any representation or warranty made by Orgenesis Parent, the Company or any of its Subsidiaries in Section 2.1 or Article 3 or in any Ancillary Agreement or (ii) any breach of any covenant or agreement of Orgenesis Parent in this Agreement or in any Ancillary Agreement. The Investor shall not be entitled to indemnification for breaches of a representation and warranty pursuant to this Article 6 with respect matters or items that are properly disclosed as exceptions to such representation and warranty in the applicable section(s) of the Disclosure Schedule and in accordance with Section 9.15.

-36-


(b)       Orgenesis Parent agrees that it shall pay and otherwise fully satisfy and discharge all Designated Pre-Closing Liabilities, and shall indemnify, defend and hold all Investor Indemnitees harmless from and against, and shall reimburse all Investor Indemnitees for, the entirety of any Adverse Consequences that any Investor Indemnitee may suffer or incur in connection with any Designated Pre-Closing Liabilities.

6.2       Indemnification by Investor. Subject to the terms and conditions of this Article 6, Investor will indemnify, defend and hold harmless Orgenesis Parent and its successors and assigns (the “Orgenesis Indemnitees”) from and against the entirety of any Adverse Consequences they may suffer or incur (including any Adverse Consequences they may suffer or incur after the end of any applicable survival period, provided that an indemnification claim with respect to such Adverse Consequence is made pursuant to this Article 6 prior to the end of any applicable survival period) resulting from, arising out of, relating to, or caused by (a) any breach of any representation or warranty made by Investor in Section 2.2 or in any Ancillary Agreement or (b) any breach of any material covenant or agreement of Investor in this Agreement.

6.3       Survival and Time Limitations. All representations, warranties, covenants and agreements of the Parties in this Agreement or any other certificate or document delivered pursuant to this Agreement will survive the Closing indefinitely subject to the following sentence. Notwithstanding the foregoing, Orgenesis Parent will have no liability with respect to any claim under Section 6.1(a)(i) unless Investor notifies Orgenesis Parent of such a claim on or before the date that is eighteen (18) months after the Closing Date (the “General Survival Date”); provided, however, that (a) any claim relating to any representation made in Section 3.9 (Legal Compliance) may be made at any time until the date that is three (3) years after the Closing Date, (b) any claim relating to any representation made in Sections 2.1(c) (Brokers’ Fees), 3.5 (Brokers’ Fees), 3.6 (Assets), 3.10 (Tax Matters), 3.12 (Intellectual Property), and 3.18 (Debt) may be made at any time until the date that is seven and a half (7.5) years after the Closing Date and, (c) any claim relating to any representation made in Sections 2.1(a) (Authorization of Transaction), 2.1(d) (Company Securities), 2.1(f) (Reorganization), 2.1(g) (Subsidiaries), 3.1 (Organization, Qualification, and Power), 3.2 (Authorization of Transaction), and 3.3 (Capitalization and Subsidiaries) may be made at any time without limitation (collectively, the representations and warranties described in clauses (a), (b) and (c) are referred to as the “Excluded Representations”) and (d) any claim related to intentional or fraudulent breaches of the representations and warranties may be made at any time without limitation. Investor will have no liability with respect to any claim for any breach or inaccuracy of any representation or warranty in this Agreement unless Orgenesis Parent notifies Investor of such a claim on or before the General Survival Date. Notwithstanding anything to the contrary contained herein, if Investor or Orgenesis Parent, as applicable, provides notice of a claim in accordance with the terms of this Agreement within the applicable time period set forth above, then liability for such claim will continue until such claim is fully resolved.

6.4       Limitations on Indemnification by Orgenesis Parent.

(a)       With respect to the matters described in Sections 6.1(a)(i), Orgenesis Parent will have no liability until Investor Indemnitees have suffered aggregate Adverse Consequences by reason of all such breaches in excess of $350,000 (the “Threshold”), after which point Orgenesis Parent will be obligated to indemnify Investor Indemnitees from and against all Adverse Consequences from dollar one; provided, that the foregoing limitations shall not apply in respect of any Adverse Consequences relating to (i) breaches of the Excluded Representations or (ii) any intentional or fraudulent breach of a representation or warranty.

-37-


(b)       With respect to the matters described in Sections 6.1(a)(i), the aggregate maximum liability of Orgenesis Parent shall be $2,500,000 (the “Cap”); provided, that the foregoing limitations shall not apply in respect of any Adverse Consequences relating to (i) breaches of the Excluded Representations or (ii) any intentional or fraudulent breach of representation or warranty.

(c)       With respect to the matters described in Sections 6.1(a)(i) relating to breach of any Excluded Representation, the aggregate maximum liability of Orgenesis Parent shall be the Purchase Price paid to the Company pursuant to this Agreement.

(d)       Investor agrees that it shall not be entitled to indemnification or have any recourse against Orgenesis Parent or the Company, solely for the Company’s failure to meet the conditions required for payment of the First Future Payment and/or Second Future Payment as set forth in Sections 1.6(a) and 1.6(b) and that Investor’s sole remedy and recourse for such failure is that the First Future Payment and/or the Second Future Payment, as applicable, shall not be earned and shall not be payable.

6.5       Limitations on Indemnification by Investor.

(a)       With respect to the matters described in Section 6.2(a), Investor will have no liability until Orgenesis Indemnitees have suffered Adverse Consequences by reason of all such breaches in excess of the Threshold, after which point Investor will be obligated to indemnify Orgenesis Indemnitees from and against all Adverse Consequences from dollar one; provided, that the foregoing limitations shall not apply in respect of any Adverse Consequences relating to (a) breaches of any representation made in Sections 2.2(a) (Organization of Investor), 2.2(b) (Authorization of Transaction), and 2.2(d) (Brokers’ Fees) or (b) any intentional or fraudulent breach of a representation or warranty.

(b)       With respect to the matters described in Section 6.2(a), the aggregate maximum liability of Investor shall be the Cap; provided, that the foregoing limitation shall not apply in respect of any Adverse Consequences relating to (i) breaches of any representation made in Sections 2.2(a) (Organization of Investor), 2.2(b) (Authorization of Transaction), and 2.2(d) (Brokers’ Fees) or (ii) any intentional or fraudulent breach of a representation or warranty.

6.6       Third-Party Claims.

(a)       If a third party initiates a claim, demand, dispute, lawsuit or arbitration (a “Third-Party Claim”) against any Person (the “Indemnified Party”) with respect to any matter that the Indemnified Party might make a claim for indemnification against any Party (the “Indemnifying Party”) under this Article 6, then the Indemnified Party must promptly notify the Indemnifying Party in writing of the existence of such Third-Party Claim and must deliver copies of any documents served on the Indemnified Party with respect to the Third-Party Claim; provided, however, that any failure on the part of an Indemnified Party to so notify an Indemnifying Party shall not limit any of the obligations of the Indemnifying Party under this Article 6 (except to the extent such failure materially prejudices the defense of such proceeding).

-38-


(b)       Upon receipt of the notice described in Section 6.6(a), the Indemnifying Party will have the right to defend the Indemnified Party against the Third-Party Claim with counsel reasonably satisfactory to the Indemnified Party, provided, that (i) the Indemnifying Party notifies the Indemnified Party in writing within fifteen (15) days after the Indemnified Party has given notice of the Third-Party Claim that the Indemnifying Party will indemnify the Indemnified Party from and against the entirety of any Adverse Consequences the Indemnified Party may suffer resulting from, arising out of, relating to, or caused by the Third-Party Claim, (ii) the Indemnifying Party provides the Indemnified Party with evidence reasonably acceptable to the Indemnified Party that the Indemnifying Party will have the financial resources to defend against the Third-Party Claim and fulfill its indemnification obligations hereunder, (iii) the Third-Party Claim involves only money damages and does not seek an injunction or other equitable relief, (iv) the Third-Party Claim does not involve any customer of the Company or any of its Subsidiaries, (v) settlement of, or an adverse judgment with respect to, the Third-Party Claim is not, in the good faith judgment of the Indemnified Party, likely to establish a precedential custom or practice adverse to the continuing business interests or the reputation of the Indemnified Party, and (vi) the Indemnifying Party conducts the defense of the Third-Party Claim actively and diligently. The Indemnifying Party will keep the Indemnified Party apprised of all material developments, including settlement offers, with respect to the Third-Party Claim and permit the Indemnified Party to participate in the defense of the Third-Party Claim. So long as the Indemnifying Party is conducting the defense of the Third-Party Claim in accordance with this Section 6.6(b), the Indemnifying Party will not be responsible for any attorneys’ fees or other expenses incurred by the Indemnified Party regarding the defense of the Third-Party Claim.

(c)       In the event that any of the conditions under Section 6.6(b) is or becomes unsatisfied, however, (i) the Indemnified Party may defend against, and consent to the entry of any judgment on, or enter into any settlement with respect to, the Third-Party Claim in any manner it may reasonably deem appropriate, (ii) the Indemnifying Parties will reimburse the Indemnified Party promptly and periodically for the costs of defending against the Third-Party Claim (including reasonable attorneys’ fees and expenses), and (iii) the Indemnifying Parties will remain responsible for any Adverse Consequences the Indemnified Party may suffer resulting from, arising out of, relating to, or caused by the Third-Party Claim to the fullest extent provided in this Article 6.

(d)       Except in circumstances described in Section 6.6(c), neither the Indemnified Party nor the Indemnifying Party will consent to the entry of any judgment or enter into any settlement with respect to the Third-Party Claim without the prior written consent of the other party, which consent will not be unreasonably withheld or delayed.

6.7       Other Indemnification Matters. All indemnification payments under this Article 6 will be deemed adjustments to the Cash Payment. For purposes of determining the amount of Adverse Consequences resulting from any misrepresentation or breach of a representation or warranty (but for the avoidance of doubt, not for purposes of determining whether there has been any misrepresentation or breach of a representation or warranty), all qualifications or exceptions in any representation or warranty relating to or referring to the terms “material”, “materiality”, “in all material respects”, “Material Adverse Effect” or any similar term or phrase shall be disregarded, it being the understanding of the Parties that for such purposes, the representations and warranties of the Parties contained in this Agreement shall be read as if such terms and phrases were not included in them. Orgenesis Parent agrees that Orgenesis Parent and its Affiliates have no claims or rights to contribution or indemnity from the Company or any of its Subsidiaries with respect to any amounts paid by Orgenesis Parent pursuant to this Article 6. The right to indemnification, payment of any losses or other remedy based on such representations and warranties (as modified by the applicable sections of the Disclosure Schedule), covenants, and obligations will not be affected by any investigation conducted with respect to, or any knowledge acquired (or capable of being acquired) at any time, whether before or after the execution and delivery of this Agreement, with respect to the accuracy or inaccuracy of or compliance with, any such representation or warranty (as modified by the applicable sections of the Disclosure Schedule), covenant, or obligation. Orgenesis Parent hereby acknowledges that, regardless of any investigation made (or not made) by or on behalf of Investor, and regardless of the results of any such investigation, Investor has entered into this transaction in express reliance upon such representations and warranties (as modified by the applicable sections of the Disclosure Schedule) covenants and obligations.

-39-


6.8       Indemnity Payments. Orgenesis Parent shall have the option to make prompt payment to an Investor Indemnitee in the entire amount of all Adverse Consequences claimed by such Investor Indemnitee (each such amount, an “Indemnity Claim”) pursuant to an indemnification claim made pursuant to this Agreement, either (a) in an amount of cash equal to the Indemnity Claim or (b) in an amount of shares of Company Preferred Stock issued by the Company equal to the quotient of (i) the Indemnity Claim divided by (ii) $31.22; provided, that if an Investor Indemnitee is the Company or any of its Subsidiaries, then the Indemnity Claim shall be satisfied in cash by Orgenesis Parent.

ARTICLE 7

TAX MATTERS

7.1       Tax Indemnification. In addition to the indemnification provisions of Article 6, Orgenesis Parent shall be liable for, and shall indemnify and hold Investor Indemnitees harmless from and against the entirety of any Adverse Consequences that any Investor Indemnitee may suffer or incur resulting from, arising out of, relating to, or caused by (a) all Taxes of Orgenesis Parent, (b) all Taxes imposed on or incurred by the Company and its Subsidiaries with respect to any Pre-Closing Tax Periods, (c) all Taxes imposed on or incurred by Orgenesis Parent, the Company or any of their Subsidiaries with respect to the Reorganization, (d) any withholding, payroll, social security, unemployment or similar Taxes caused by or resulting from the sale or issuance of the Company Preferred Stock, (e) all Taxes of any Person imposed on any of the Company or any of its Subsidiaries as a transferee or successor, by contract or otherwise, which Taxes relate to an event or transaction occurring before the Closing, and (f) all Taxes of any member of an affiliated, consolidated, combined, or unitary group of which the Company or its Subsidiaries (or any predecessor) is or was a member on or prior to the Closing Date, including pursuant to Treasury Regulation Section 1.1502 -6 or any analogous or similar state, local, or foreign Law.

-40-


7.2       Responsibility for Filing Tax Returns for Periods through Closing Date. The Company shall prepare or cause to be prepared and file or cause to be filed all Tax Returns for the Company and its Subsidiaries that are filed after the Closing Date. The Company shall permit Investor to review, comment and consent with respect to each such Tax Return related to a Pre-Closing Tax Period prior to filing and shall make such revisions as are reasonably requested by Investor.

7.3       Straddle Periods. For purposes of this Article, in the case of any Taxes that are imposed on a periodic basis and are payable for a Tax period that includes (but does not end on) the Closing Date, the portion of such Tax that relates to the Pre-Closing Tax Period will (a) in the case of any Taxes other than Taxes based upon or related to income or receipts, be deemed to equal the amount of such Tax for the entire Tax period multiplied by a fraction the numerator of which is the number of days in the Tax period ending on the Closing Date and the denominator of which is the number of days in the entire Tax period, and (b) in the case of any Tax based upon or related to payroll, income or receipts, be deemed to equal the amount that would be payable if the relevant Tax period ended on the Closing Date.

7.4       Cooperation on Tax Matters. Investor and Orgenesis Parent will cooperate, as and to the extent reasonably requested by the other Party, in connection with the filing and preparation of Tax Returns pursuant to this Article and any Proceeding related thereto. Such cooperation will include the retention and (upon the other Party’s request) the provision of records and information that are reasonably relevant to any such Proceeding and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. Investor and Orgenesis Parent will retain all books and records with respect to Tax matters pertinent to the Company and its Subsidiaries relating to any Tax period beginning before the Closing Date until thirty (30) days after the expiration of the statute or period of limitations of the respective Tax periods.

7.5       Certain Taxes. All transfer (including real estate transfer), documentary, sales, use, stamp, registration and other such Taxes and fees (including any penalties and interest) incurred in connection with this Agreement or the Transactions will be paid by Orgenesis Parent when due, and Orgenesis Parent will, at its own expense, file all necessary Tax Returns and other documentation with respect to all such transfer, documentary, sales, use, stamp, registration and other Taxes and fees, and, if required by applicable Law, the Company and Investor will join in the execution of any such Tax Returns and other documentation.

ARTICLE 8

DEFINITIONS

Accountants” has the meaning set forth in Section 1.5.

Adverse Consequences” means all actions, suits, Proceedings, charges, complaints, claims, Orders, dues, penalties, fines, costs, amounts paid in settlement, liabilities, obligations, Taxes, Liens, losses, damages, deficiencies, costs of investigation, court costs, and other expenses (including interest, penalties and reasonable attorneys’ fees and expenses, whether in connection with Third-Party Claims or claims among the Parties related to the enforcement of the provisions of this Agreement.

-41-


Advisory Services Agreements” means that certain Advisory Services Agreement dated as of the date hereof between the Company and Great Point Partners, LLC, and that certain Transaction Services Agreement dated as of the date hereof between the Company and GPP Securities, LLC, each in the applicable form attached hereto as Exhibit A.

Affiliate” means, with respect to the Person to which it refers, (a) a Person that directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with, such Person, (b) any officer, director, manager or equityholder of such Person, (c) any parent, sibling, descendant or spouse of such Person or of any of the Persons referred to in clauses (a) and (b), and (d) any corporation, limited liability company, general or limited partnership, trust, association or other business or investment entity that directly or indirectly, through one or more intermediaries controls, is controlled by or is under common control with any of the foregoing individuals. For purposes of this definition, the term “control” of a Person shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies, whether through the ownership of voting securities, by Contract or otherwise.

Agreement” has the meaning set forth in the preface.

Amended and Restated Certificate of Incorporation” means that certain Amended and Restated Certificate of Incorporation of the Company filed with the State of Delaware as of the date hereof, in the form of Exhibit B attached hereto.

Ancillary Agreements” means all of the agreements, documents and instruments executed and delivered pursuant to this Agreement or the Reorganization.

Applicable Area” means (a) anywhere in the world, but if such area is determined by judicial action to be too broad, then it means (b) Europe, North America and Asia, but if such area is determined by judicial action to be too broad, then it means (c) any country in which Orgenesis Parent, the Company or their Subsidiaries engaged in Business prior to the Closing Date, but if such area is determined by judicial action to be too broad, then it means (d) any state or locality within any country in which Orgenesis Parent, the Company or their Subsidiaries engaged in Business prior to the Closing Date.

Business” means the business of providing manufacturing and development services to third parties related to cell and gene therapy products, processes and solutions and providing related manufacturing or development services, and the creation and development of technology, Intellectual Property, tools and optimizations in connection with such manufacturing and development services for third parties; provided, however, that notwithstanding the foregoing, research, manufacturing, development and all other activities related to the development, discovery, manufacturing and commercialization of therapeutic products and the process, methods or services thereof (including, without limitation, such therapeutic products in which Orgenesis Parent has an economic interest or any relationship with any Third Party in which Orgenesis has an economic interest or that are created, developed, manufactured or sold by a joint venture, partnership or collaboration between Orgenesis and a Third Party) with a Third Party shall not, for purposes of this Agreement, be considered part of the “Business”.

-42-


Business Day” means any day that is not a Saturday, Sunday or any other day on which banks are required or authorized by Law to be closed in New York, New York.

Cap” has the meaning set forth in Section 6.4(b).

Cash” means the aggregate amount of cash and cash equivalents of the Company and its Subsidiaries on a consolidated basis as of the Closing Date as determined in accordance with GAAP, excluding any Restricted Cash; provided, that if such aggregate amount of cash and cash equivalents is a negative number, then it shall include the amount of all fees, penalties or interest related to such negative amount of Cash.

Cash Payment” means the amount equal to (a) $11,800,000, minus (b) the Working Capital Deficit, if any, minus (c) the Debt Amount, minus (d) the Cash Shortfall, if any.

Cash Payment Shortfall” has the meaning set forth in Section 1.4(b).

Cash Shortfall” means the amount (if any) by which the amount of Cash is less than the Required Cash.

Change of Control Transaction” has the meaning set forth in Section 9.18.

Closing” has the meaning set forth in Section 1.9.

Closing Date” has the meaning set forth in Section 1.9.

Closing Statement” has the meaning set forth in Section 1.5.

Code” means the Internal Revenue Code of 1986, as amended, and any applicable rules and regulations thereunder, and any successor to such statute, rules or regulations.

Company” has the meaning set forth in the preface.

Company Common Stock” has the meaning set forth in Section 3.3(a).

Company Insurance Agreements” has the meaning set forth in Section 3.14.

Company Preferred Stock” has the meaning set forth in Section 1.1.

Company Securities” has the meaning set forth in Section 3.3(a).

Confidential Information” means any information concerning the Company or the Business and the business and affairs of the Company and its Subsidiaries not already generally available to the public.

-43-


Consent” means, with respect to any Person, any consent, approval, authorization, permission or waiver of, or registration, declaration or other action or filing with or exemption by such Person.

Contract” means any oral or written contract, obligation, understanding, commitment, lease, license, purchase order, bid or other agreement.

Copyrights” has the meaning set forth in Section 3.12(c).

Customer” means any Person who (a) purchased or licensed services of the Business from the Company or any of its Subsidiaries (or their predecessors) during the three (3) years prior to the Closing Date, (b) was called upon or solicited by the Company or any of its Subsidiaries (or their predecessors) during such three (3) year period if such solicitation relates to the Business, or (c) was a distributor, sales representative, agent or broker for the Company or any of its Subsidiaries during such three (3) year period with respect to the Business. Notwithstanding the foregoing, the term “Customer” shall not include (i) any Third Party or (ii) any Person purchasing or licensing products from or providing or receiving services from/to the Company that do not relate to the Business.

Debt” means any (a) obligations relating to indebtedness for borrowed money, (b) obligations evidenced by bonds, notes, debentures or similar instruments, (c) obligations in respect of capitalized leases (calculated in accordance with GAAP), (d) the principal or face amount of banker’s acceptances, surety bonds, performance bonds or letters of credit (in each case whether or not drawn), (e) obligations for the deferred purchase price of property or services, including, without limitation, the maximum potential amount payable with respect to earnouts, purchase price adjustments or other payments related to acquisitions (other than current accounts payable to suppliers and similar accrued liabilities incurred in the Ordinary Course of Business, paid in a manner consistent with industry practice and reflected as a current liability in the final calculation of Working Capital), (f) obligations under any existing interest rate, commodity or other swap, hedge or financial derivative agreement entered into by the Company or its Subsidiaries prior to Closing, (g) Off-Balance Sheet Financing of the Company or its Subsidiaries in existence immediately prior to the Closing, (h) other long term or non-ordinary course liabilities, (i) obligations relating to any annual bonuses of employees of the Company and its Subsidiaries for the calendar year 2017 or prior (including any payroll, employment or other Taxes required to be paid in connection therewith), (j) obligations relating to any Taxes imposed on or incurred by the Company and its Subsidiaries with respect to all periods prior to the Closing Date to the extent not included in Working Capital, (k) obligations related to any deferred compensation or other unfunded or underfunded retirement or pension plan, fund, program, or other benefits of the Company or its Subsidiaries (including any amounts the Company or any of its Subsidiaries are required to pay in connection with defined contribution schemes (including any minimum returns related thereto)), (l) all accounts payable of the Company and its Subsidiaries that have been outstanding for more than 90 days, (m) indebtedness or obligations of the types referred to in the preceding clauses (a) through (l) of any other Person secured by any Lien on any assets of the Company or any of its Subsidiaries, even though the Company and its Subsidiaries have not assumed or otherwise become liable for the payment thereof, and (n) obligations in the nature of guarantees of obligations of the type described in clauses (a) through (l) above of any other Person, in each case together with all accrued interest thereon and any applicable prepayment, redemption, breakage, make-whole or other premiums, fees or penalties.

-44-


Debt Amount” means all Debt of the Company and its Subsidiaries (on a consolidated basis) as of the Closing Date plus, without duplication, any amounts required to fully pay or otherwise satisfy all such Debt (including, but not limited to, any prepayment premium or penalty, breakage costs, accrued interest and costs and expenses).

Designated Courts” has the meaning set forth in Section 9.17.

Designated Intellectual Property” has the meaning set forth in Section 3.12(c).

Designated Pre-Closing Liabilities” means any liability or obligation of the Company and its Subsidiaries other than: (a) liabilities for accounts payable, accrued expenses and other current liabilities of the Company and its Subsidiaries as of the Closing to the extent accrued for and reflected as a current liability in the final calculation of Working Capital; (b) liabilities and obligations for accrued wages, commissions, annual bonuses, accrued vacation and other amounts payable to the Company’s and its Subsidiaries’ employees as of the Closing to the extent specifically accrued for and reflected as a current liability in the final calculation of Working Capital; and (c) liabilities under Contracts first arising or becoming payable after the Closing Date, excluding, however, any such liabilities resulting from or relating to any breach, default, violation or occurrence of a contingency thereunder occurring on or prior to the Closing Date.

Disclosure Schedule” means the disclosure schedule delivered by Orgenesis Parent and the Company to Investor on the date hereof.

EBITDA” means, for the relevant time period, the amount equal to the sum of (a) Net Income attributable to the Company during such period, plus (b) to the extent (but only to the extent) deducted in determining such Net Income attributable to the Company, without duplication, (i) all interest expense for such period, (ii) all charges against Net Income for such period for federal, state and local income Taxes and deferred tax charges, (iii) all depreciation expenses for such period, and (iv) all amortization expenses for such period, and (iv) any extraordinary expenses or losses (including losses on the sale of assets outside the Ordinary Course of Business) to the extent realized during such period (subject to the Investor’s approval of any such “add back” items (such approval not to be unreasonably withheld)) minus (c) to the extent (but only to the extent) added in determining such Net Income attributable to the Company (i) all interest income during such period and (ii) any extraordinary income or gains (including gains on the sales of assets outside of the Ordinary Course of Business), to the extent realized during such period. Notwithstanding anything in this Agreement to the contrary, (x) if the Company or any of its Subsidiaries engages in an acquisition, joint venture or similar transaction prior to the end of the applicable Measurement Period, then EBITDA will be calculated without giving effect to such acquisition, joint venture or similar transaction (or the business acquired thereby), (y) the initial costs and expenses of organizing and establishing the operations of the Company’s Subsidiary based in the United States shall not be included in any calculation of EBITDA, (z) all inter-company revenues, costs and expenses among the Company and any of its Subsidiaries shall be eliminated for purposes of calculating EBITDA, (aa) all non-cash expenses (such as for example stock based compensation) shall not be included in any calculation of EBITDA, (bb) during the period beginning on the Closing Date and ending two (2) years after the Closing Date only, the cost of the annual compensation of Darren Head and any Chief Financial Officer of the Company hired after the date hereof shall not be included in any calculation of EBITDA, and (cc) all management fees paid by the Company pursuant to Section 6 of that certain Advisory Services Agreement dated as of the date hereof between the Company and Great Point Partners, LLC shall not be included in any calculation of EBITDA.

-45-


Employee Benefit Plan” means any (a) pension plan or deferred compensation or retirement plan, fund, program, or arrangement, (b) equity-based plan, program, or arrangement (including any stock or equity interest option, stock or equity interest purchase, stock or equity interest ownership, stock or equity interest appreciation, phantom stock or equity interest, or restricted stock or equity interest plan) or (c) other retirement, severance, bonus, profit-sharing, incentive, health, dental, medical, surgical, hospital, indemnity, welfare, sickness, accident, disability, death, apprenticeship, training, day care, scholarship, tuition reimbursement, education, adoption assistance, prepaid legal services, termination, unemployment, vacation or other paid time off, change in control, or other similar plan, fund, program, or arrangement, whether written or unwritten, that is sponsored, maintained, or contributed to, or required to be maintained or contributed to, by the Company or any of its Subsidiaries or any other Person for the benefit of any present or former officers, employees, agents, directors, consultants, or independent contractors of the Company or any of its Subsidiaries.

Employment Agreement” means that certain Employment Agreement dated as of the date hereof between the Company and Darren Head, in the form of Exhibit C attached hereto.

Environmental, Health, and Safety Requirements” means all Laws and Orders concerning public health and safety, worker and occupational health and safety, natural resources and pollution or protection of the environment, including all those relating to the presence, use, production, generation, handling, transportation, treatment, storage, disposal, distribution, labeling, testing, processing, discharge, release, threatened release, control, or cleanup of any Hazardous Substances, materials, or wastes, chemical substances, or mixtures, pesticides, pollutants, contaminants, toxic chemicals, petroleum products or byproducts, fuel oil products and byproducts, mold, asbestos, polychlorinated biphenyls, noise, or radiation.

Estimated Cash Payment” has the meaning set forth in Section 1.3.

Excluded Representations” has the meaning set forth in Section 6.3.

Final Cash Payment” has the meaning set forth in Section 1.5.

Financial Statements” has the meaning set forth in Section 3.7(a).

First Future Payment” has the meaning set forth in Section 1.6(a).

First Period EBITDA Shortfall” has the meaning Section 1.6.

First Period Net Revenue Shortfall” has the meaning Section 1.6.

-46-


First Measurement Period” has the meaning set forth in Section 1.6(a).

First Milestones” has the meaning set forth in Section 1.6(a).

Future Payments” means the First Future Payment and the Second Future Payment, collectively.

Future Payment Objections Statement” has the meaning specified in Section 1.7.

Future Payment Report” has the meaning specified in Section 1.7.

GAAP” means generally accepted accounting principles in the United States as set forth in pronouncements of the Financial Accounting Standards Board (and its predecessors) and the American Institute of Certified Public Accountants.

General Survival Date” has the meaning set forth in Section 6.3.

Governmental Body” means any foreign or domestic federal, state or local government or quasi-governmental authority or any department, agency, subdivision, court or other tribunal of any of the foregoing.

Hazardous Substances” means (a) petroleum or petroleum products, flammable materials, explosives, radioactive materials, radon gas, lead-based paint, asbestos in any form, urea formaldehyde foam insulation, polychlorinated biphenyls (PCBs), transformers or other equipment that contain dielectric fluid containing PCBs and toxic mold or fungus of any kind or species, (b) any chemicals or other materials or substances which are defined as or included in the definition of “hazardous substances,” “hazardous wastes,” “hazardous materials,” “toxic substances,” “toxic pollutants,” “contaminants,” “pollutants,” or words of similar import under any applicable Environmental, Health, and Safety Requirements, and (c) any other chemical, material or substance exposure to which is prohibited, limited or regulated under any applicable Environmental, Health, and Safety Requirements.

Improvements” means all buildings, structures, fixtures, building systems and equipment, and all components thereof (including the roof, foundation and structural elements), included in the Leased Real Property.

Indemnified Party” has the meaning set forth in Section 6.6(a).

Indemnifying Party” has the meaning set forth in Section 6.6(a).

Indemnity Claim” has the meaning set forth in Section 6.8.

Intellectual Property” means all intellectual property, whether registered or unregistered, including the following in any jurisdiction throughout the world: (a) all inventions (whether patentable or unpatentable and whether or not reduced to practice), all improvements thereto, and all patents, patent applications, and patent disclosures, together with all reissuances, continuations, continuations-in-part, divisions, extensions, and reexaminations thereof, (b) all trademarks, service marks, trade dress, logos, slogans, trade names (including social media user names), corporate and business names, Internet domain names, and rights in telephone numbers, together with all translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all applications, registrations, and renewals in connection therewith, (c) all copyrightable works, all copyrights, and all applications, registrations, and renewals in connection therewith, (d) all mask works and all applications, registrations, and renewals in connection therewith, (e) all trade secrets and confidential business information (including ideas, research and development, know-how, formulas, compositions, manufacturing and production processes and techniques, technical data and information, data rights, materials designs, drawings, specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals), (f) all Software, (g) all material advertising and promotional materials, (h) all other proprietary rights, and (i) all copies and tangible embodiments thereof (in whatever form or medium). Intellectual Property of the Company shall include any such Intellectual Property listed in the relevant schedules of the Disclosure Schedule.

-47-


 “Intellectual Property Agreements” means any Contract pursuant to which the Company or any of its Subsidiaries uses Intellectual Property which is not owned by the Company or one of its Subsidiaries or pursuant to which the Company or any of its Subsidiaries grants any other Person the any rights with respect to any Intellectual Property owned or licensed by the Company or any of its Subsidiaries.

 “Investor” has the meaning set forth in the preface.

 “Investor Expenses” means any and all legal, accounting, tax, financial advisory and other professional or transaction related costs, fees and expenses incurred by Great Point Partners, LLC, Investor or their Affiliates in connection with this Agreement or in investigating, pursuing or completing the Transactions (including any amounts owed to any consultants, auditors, accountants, attorneys, brokers or investment bankers), as evidenced by appropriate written invoices.

 “Investor Indemnitees” has the meaning set forth in Section 6.1(a). “Israel Sub” has the meaning set forth in the Preliminary Statements.

 “Knowledge” means (a) in the case of an individual, the actual knowledge of such individual, upon reasonable inquiry and (b) in the case of Orgenesis Parent, the Company, and their Subsidiaries, the actual knowledge of Vered Caplan, Fred Tonglet, David Kim, Ohad Karnieli, Nufar Gross and Denis Bedoret in each case upon reasonable inquiry of such Person’s direct reports who hold executive office or management positions.

 “Law” means any foreign or domestic federal, state or local law, statute, code, ordinance, regulation, rule, directive, consent agreement, constitution or treaty of any Governmental Body, including common law.

 “Leased Real Property” means all leasehold or subleasehold estates and other rights to use or occupy any land, buildings, structures, Improvements, fixtures or other interest in real property held by the Company or any of its Subsidiaries.

-48-


 “Leases” means all written or oral leases, subleases, licenses, easements, concessions and other agreements, including all amendments, extensions, renewals, guaranties, and other agreements with respect thereto, pursuant to which the Company or any of its Subsidiaries holds any Leased Real Property.

 “Lien” means any lien, mortgage, pledge, encumbrance, charge, security interest, adverse claim, liability, interest, charge, preference, priority, proxy, transfer restriction (other than restrictions under the Securities Act and state securities Laws), encroachment, Tax, order, community property interest, equitable interest, option, warrant, right of first refusal, easement, profit, license, servitude, right of way, covenant, condition or zoning restriction.

 “Material Adverse Effect” means any event, change, development, or effect that, individually or in the aggregate, will or could reasonably be expected to have a materially adverse effect on (a) the business, operations, assets (including intangible assets), liabilities, operating results, or financial condition of the Company or any of its Subsidiaries or (b) the ability of the Company or Orgenesis Parent to consummate timely the Transactions.

 “Material Contracts” means, collectively, the Contracts required to be listed in Section 3.13(a) of the Disclosure Schedule, the Leases, the Intellectual Property Agreements, and the Company Insurance Agreements.

 “Material Customers” has the meaning set forth in Section 3.22(a).

Material Vendors” has the meaning set forth in Section 3.22(a).

 “Measurement Periods” means the First Measurement Period and the Second Measurement Period, collectively.

 “Most Recent Balance Sheet” means the balance sheet contained within the Most Recent Financial Statements.

 “Most Recent Financial Statements” has the meaning set forth in Section 3.7(a).

Most Recent Fiscal Month End” has the meaning set forth in Section 3.7(a) .

 “Most Recent Fiscal Year End” has the meaning set forth in Section 3.7(a).

 “Net Income” means, for any period of determination, net earnings (or net loss) of the Company and its Subsidiaries on a consolidated basis for such period, but excluding (without duplication) (a) any income or gains or losses from the collection of the proceeds of any insurance policies or settlements, (b) any restoration to income of any contingency reserve, except to the extent that provision for such reserve was made out of income accrued during the Measurement Periods, (c) any income or gain or loss during such period from (i) any prior period adjustments resulting from any change in accounting principles in accordance with GAAP or (ii) any discontinued operations or disposition thereof, and (d) any income or gains or losses resulting from the retirement or extinguishment of Debt or the acquisition of any securities.

 “Net Names” has the meaning set forth in Section 3.12(h).

-49-


  "Net Revenue”means, for the relevant time period, the revenue (net of discounts, returns, price adjustments, refunds, rebates, credits, offsets and allowances) generated by the Company and its Subsidiaries on a consolidated basis for such time period. Notwithstanding anything in this Agreement to the contrary, if the Company or any of its Subsidiaries engages in an acquisition, joint venture, disposition or similar transaction prior to the end of the applicable Measurement Period, then Net Revenue will be calculated without giving effect to such acquisition, joint venture, disposition or similar transaction (or the business acquired thereby).

 “Objections Statement” has the meaning set forth in Section 1.5.

 “Off-Balance Sheet Financing” means (a) any liability of the Company or any of its Subsidiaries under any sale and leaseback transactions which does not create a liability on the consolidated balance sheet of the Company and (b) any liability of the Company or any of its Subsidiaries under any synthetic lease, Tax retention operating lease, off-balance sheet loan or similar off-balance sheet financing product where the transaction is considered indebtedness for borrowed money for federal income Tax purposes but is classified as an operating lease in accordance with GAAP for financial reporting purposes.

 “Order” means any foreign or domestic order, award, decision, injunction, judgment, ruling, decree, charge, writ, subpoena or verdict entered, issued, made or rendered by any Governmental Body or arbitrator.

 “Ordinary Course of Business” means the ordinary course of business consistent with past custom and practice (including with respect to quantity and frequency).

 “Organizational Documents” means (a) any certificate or articles of incorporation, bylaws, certificate or articles of formation, operating agreement or partnership agreement, (b) any documents comparable to those described in clause (a) as may be applicable pursuant to any Law, and (c) any amendment or modification to any of the foregoing.

 “Orgenesis Indemnitees” has the meaning set forth in Section 6.2.

 “Orgenesis Manufacturing Agreement” has the meaning set forth in Section 3.21(b).

 “Orgenesis Parent” has the meaning set forth in the preface.

 “Orgenesis Transaction Expenses” means any and all (a) legal, accounting, tax, financial advisory, environmental consultants and other professional or transaction related costs, fees and expenses incurred by Orgenesis Parent, its Affiliates, the Company or any of its Subsidiaries in connection with this Agreement or in investigating, pursuing or completing the Transactions (in each case including any amounts owed to any consultants, auditors, accountants, attorneys, brokers or investment bankers), (b) payments, bonuses or severance which become due or are otherwise required to be made by Orgenesis Parent, its Affiliates, the Company or any of its Subsidiaries as a result of or in connection with the Closing or as a result of any change of control or other similar provisions, and (c) payroll, employment or other Taxes, if any, required to be paid by Orgenesis Parent, its Affiliates, the Company or any of its Subsidiaries with respect to the amounts payable pursuant to this Agreement, the amounts described in clause (a) and (b), or the forgiveness of any loans or other obligations owed by Orgenesis Parent or employees in connection with the Transactions.

-50-


 “Party” has the meaning set forth in the preface.

 “Patents” has the meaning set forth in Section 3.12(c)(i).

 “Permit” means any license, import license, export license, franchise, Consent, permit, certificate, certification, certificate of occupancy or Order issued by any Person.

 “Permitted Lien” means any (a) statutory liens for Taxes not yet due or payable or for Taxes that the Company or any of its Subsidiaries are contesting in good faith through appropriate proceedings in a timely manner, in each case for which adequate reserves have been established and shown on the Most Recent Balance Sheet, (b) statutory liens of landlords, carriers, warehousemen, workmen, repairmen, mechanics, materialmen and similar liens arising in the Ordinary Course of Business and not incurred in connection with the borrowing of money, (c) restrictions, easements, covenants, reservations, rights of way or other similar matters of title to the Leased Real Property of record, and (d) zoning ordinances, restrictions, prohibitions and other requirements imposed by any Governmental Body, all of which do not materially interfere with the conduct of the Business.

 “Person” means any individual, corporation, partnership, limited liability company, firm, joint venture, association, joint-stock company, trust, unincorporated organization, Governmental Body or other entity.

 “Personal Information” refers to data that, separately or when combined with other data, can be used to identify an individual person, including, without limitation, name, address, email address, photograph, IP address, and unique device identifier.

 “Pre-Closing Tax Period” means any taxable period ending on or before the Closing Date and the portion through the end of the Closing Date for any taxable period that includes (but does not end on) the Closing Date.

 “Privacy Laws” means all Laws and industry self-regulatory programs concerning the creation, receipt, maintenance, transmission, use, disclosure, processing, protection, collection, analysis, retention, storage, privacy, security, breach, transfer, destruction, or disposal of Personal Information including, without limitation, foreign, state and local consumer protection Laws, foreign, state and local breach notification Laws.

 “Proceeding” means any foreign or domestic action, hearing, proceeding, audit, lawsuit, litigation, grievance, investigation or arbitration (in each case, whether civil, criminal or administrative) pending by or before any Governmental Body or arbitrator.

 “Proper Approval” has the meaning set forth in Section 1.6(a).

 “Properly Approved” has the meaning set forth in Section 1.6(a).

 “Purchase Price” has the meaning set forth in Section 1.2.

-51-


 “QMS License Agreement” has the meaning set forth in Section 4.11.

 “Receivables” has the meaning set forth in Section 3.7(c).

 “Released Claims” has the meaning set forth in Section 4.8.

 “Released Parties” has the meaning set forth in Section 4.8.

 “Releasors” has the meaning set forth in Section 4.8.

 “Reorganization” has the meaning set forth in the Preliminary Statements.

 “Required Cash” means an amount of Cash equal to $2,407,771.

 “Restricted Cash” means any Cash held in escrow, any deposits, Cash held for, or on behalf of, or owed to, any clients or customers and any other Cash if the use of, or access to, such Cash is restricted.

 “Restricted Period” means a period of four (4) years following Closing.

 “Rule 144” has the meaning set forth in Section 2.2(j).

 “Second Future Payment” has the meaning set forth in Section 1.6(b).

 “Second Measurement Period” has the meaning set forth in Section 1.6(b).

 “Second Milestones” has the meaning set forth in Section 1.6(b).

 “Securities” has the meaning set forth in Section 2.2(g).

 “Securities Act” means the Securities Act of 1933, as amended, and any applicable rules and regulations thereunder, and any successor to such statute, rules or regulations.

 “Securities Exchange Act” means the Securities Exchange Act of 1934, as amended, and any applicable rules and regulations thereunder, and any successor to such statute, rules or regulations.

 “Software” means computer software programs (and all enhancements, versions, releases, and updates thereto), including software compilations, software tool sets, compilers, higher level or “proprietary” languages and all related programming and user documentation, whether in source code, object code or human readable form, or any translation or modification thereof that substantially preserves its original identity.

 “South Korea Sub” has the meaning set forth in the Preliminary Statements.

 “Stockholders’ Agreement” means that certain Stockholders’ Agreement of the Company dated as of the date hereof among the Company, Investor and Orgenesis Parent, in the form of Exhibit D attached hereto.

-52-


 “Stockholders’ Agreement Terms” means Sections 3.2, 3.5, 3.7, 3.9, 3.10, 3.11, 3.12 and Article 4 of the Stockholders’ Agreement, that must be approved by the shareholders of Orgenesis Parent.

 “Subsidiary” means, with respect to any Person, any corporation, limited liability company, partnership, association, or other entity of which (a) if a corporation, fifty percent (50%) or more of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers, or trustees thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof or (b) if a limited liability company, partnership, association, or other entity (other than a corporation), fifty percent (50%) or more of partnership or other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more Subsidiaries of that Person or a combination thereof and for this purpose, a Person or Persons also owns fifty percent (50%) or more of an interest in any entity if such Person or Persons shall be allocated fifty percent (50%) or more of such entity’s gains or losses or shall be or control any manager, management board, managing director or general partner of such entity. The term “Subsidiary” shall include all Subsidiaries of such Subsidiary and for the avoidance of doubt the South Korea Sub and the Israel Sub are considered Subsidiaries of the Company.

 “Subsidiary Proceeds” has the meaning set forth in Section 1.10.

 “Systems” has the meaning set forth in Section 3.20.

 “Tax” or “Taxes” means any federal, state, local and foreign net income, alternative or add-on minimum, estimated, gross income, gross receipts, sales, use, ad valorem, value added, transfer, franchise, capital profits, lease, service, license, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, abandoned property or escheat, environmental or windfall profit tax, customs duty or other tax, governmental fee or other like assessment or charge of any kind whatsoever (and any liability incurred or borne by virtue of the application of Treasury Regulation Section 1.1502 -6 (or any similar or corresponding provision of state, local or foreign Law), as a transferee or successor, by contract or otherwise), together with all interest, penalties, additions to tax and additional amounts with respect thereto.

 “Tax Return” means any return, declaration, report, claim for refund, or information return or statement relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.

 “Third Party” means any entity other than the Company or the Subsidiaries with whom Orgenesis Parent or any of its Subsidiaries has a collaboration, joint venture, partnership or similar economic relationship for the development of a product with therapeutic use where the primary purpose of such collaboration, joint venture, partnership or relationship is not manufacturing related to such product.

 “Third-Party Claim” has the meaning set forth in Section 6.6(a).

 “Threshold” has the meaning set forth in Section 6.4(a).

-53-


 “Trademarks” has the meaning set forth in Section 3.12(c)(ii).

 “Transactions” means all of the transactions contemplated by this Agreement and the Ancillary Agreements, including but not limited to, the Reorganization.

 “Working Capital” means an amount equal to (a) the amount of the current assets (excluding Cash, Restricted Cash and income Tax assets) of the Company and its Subsidiaries, minus (b) the amount of the current liabilities (excluding Cash, Debt, income Tax liabilities and all accounts payable of the Company and its Subsidiaries that have been outstanding for more than 90 days) of the Company and its Subsidiaries, in each case determined on a consolidated basis, consistently with the calculation and principles set forth on Schedule 8.1. For purposes of clarity, Orgenesis Transaction Expenses shall not be accrued as a liability but shall be paid by Orgenesis Parent, and the Working Capital shall be otherwise calculated as if the Transactions had not occurred.

 “Working Capital Deficit” means the amount by which the Working Capital as of the Closing Date is less than negative Four Million Nine Hundred Sixty-One Thousand Six Hundred Ninety Dollars (-$4,961,690).

ARTICLE 9

MISCELLANEOUS

 9.1       Press Releases and Public Announcements. No press release or any public announcement relating to the subject matter of this Agreement shall be made by any Party without the prior written approval of the other Parties, except (i) the approved press release attached hereto as Schedule 9.1 and (ii) any press release or public announcement that is required by applicable Law, in which case the Party required to make the press release or announcement will allow the other Parties reasonable time to comment on such press release or announcement in advance of issuance and shall incorporate such comments into such press release or announcement. Notwithstanding the foregoing, after the Closing, the Company and Investor shall be permitted to issue press releases, make public announcements and communicate with employees, customers and suppliers of Orgenesis Parent.

 9.2        No Third-Party Beneficiaries. This Agreement shall not confer any rights or remedies upon any Person other than the Parties and their respective successors and permitted assigns.

 9.3        Entire Agreement. This Agreement (including the documents referred to herein) constitutes the entire agreement among the Parties and supersedes any prior understandings, agreements, or representations by or among the Parties, written or oral, to the extent they relate in any way to the subject matter hereof.

 9.4       Succession and Assignment. This Agreement shall be binding upon and inure to the benefit of the Parties named herein and their respective successors and permitted assigns. No Party may assign either this Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of Investor and Orgenesis Parent; provided, however, that Investor may (a) assign any or all of its rights and interests hereunder to one or more of its Affiliates and designate one or more of its Affiliates to perform its obligations hereunder (in any or all of which cases Investor nonetheless shall remain responsible for the performance of all of its obligations hereunder) for reorganization purposes; provided, that such assignment is not to a competitor of the Company and its Subsidiaries, (b) assign its rights under this Agreement for collateral security purposes to any lenders providing financing to Investor, the Company or any of their respective Subsidiaries or Affiliates; provided, that such lender is approved by Orgenesis Parent (such approval not to be unreasonably withheld), or (c) assign its rights under this Agreement to any Person that acquires the Company or any of its Subsidiaries or any of their assets or any of Investor’s equity interests in the Company. Notwithstanding the foregoing, Orgenesis Parent may assign its rights under this Agreement without the prior written approval of Investor to any Person that acquires the Company or any of its Subsidiaries or any of their assets.

-54-


 9.5      Counterparts. This Agreement may be executed in one or more counterparts (including by means of facsimile or via email in electronic or portable document format (.pdf) signature pages), each of which shall be deemed an original but all of which together will constitute one and the same instrument.

 9.6       Headings. The section headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement.

 9.7      Notices. All notices, requests, demands, claims, and other communications hereunder will be in writing. Any notice, request, demand, claim, or other communication hereunder shall be deemed duly given (a) when delivered personally to the recipient, (b) when sent by electronic mail or facsimile, on the date of transmission to such recipient, (c) one (1) Business Day after being sent to the recipient by reputable overnight courier service (charges prepaid), or (d) four (4) Business Days after being mailed to the recipient by certified or registered mail, return receipt requested and postage prepaid, and addressed to the intended recipient as set forth below:

  If to Orgenesis Orgenesis Inc.
  Parent: 20271 Goldenrod Lane
    Germantown, MD 20876
    Attention: Vered Caplan
    Fax: 646-878-0801
    Email: vered.c@orgenesis.com
     
  Copy to: Pearl Cohen Zedek Latzer Baratz LLP
  1500 Broadway  
    New York, NY 10036
    Attention: Mark Cohen
    Fax: 646-878-0801
    Email: MCohen@PearlCohen.com

-55-



  If to the Company: Masthercell Global Inc.
    c/o Pearl Cohen Zedek Latzer Baratz LLP
  1500 Broadway  
    New York, NY 10036
    Attention: Mark Cohen, Esq.
  Fax: 646-878-0801  
    Email: vered.c@orgenesis.com
     
  Copy to: Pearl Cohen Zedek Latzer Baratz LLP
  1500 Broadway  
    New York, NY 10036
    Attention: Mark Cohen
  Fax: 646-878-0801  
    Email: MCohen@PearlCohen.com
     
  Copy to: GPP-II Masthercell, LLC
    c/o Great Point Partners, LLC
    165 Mason Street, 3rd Floor
    Greenwich, CT 06830
    Attention: Noah F. Rhodes, III
    Fax: (203) 971-3320
    Email: nrhodes@gppfunds.com
     
  Copy to Investor McDermott Will & Emery LLP
  Counsel: 444 West Lake Street, Suite 4000
    Chicago, Illinois 60606
    Attention: Brooks B. Gruemmer
    Fax: (312) 984-7700
    Email: bgruemmer@mwe.com
     
  Copy to: Orgenesis Inc.
    20271 Goldenrod Lane
    Germantown, MD 20876
    Attention: Vered Caplan
  Fax: 646-878-0801  
    Email: vered.c@orgenesis.com
     
  Copy to: Pearl Cohen Zedek Latzer Baratz LLP
  1500 Broadway  
    New York, NY 10036
    Attention: Mark Cohen
  Fax: 646-878-0801  
    Email: MCohen@PearlCohen.com

-56-



  If to Investor: GPP-II Masthercell, LLC
    c/o Great Point Partners, LLC
    165 Mason Street, 3rd Floor
    Greenwich, CT 06830
    Attention: Noah F. Rhodes, III
    Fax: (203) 971-3320
    Email: nrhodes@gppfunds.com
     
  Copy to Investor McDermott Will & Emery LLP
  Counsel: 444 West Lake Street, Suite 4000
    Chicago, Illinois 60606
    Attention: Brooks B. Gruemmer
    Fax: (312) 984-7700
    Email: bgruemmer@mwe.com

Any Party may change the address to which notices, requests, demands, claims, and other communications hereunder are to be delivered by giving the other Parties notice in the manner herein set forth.

 9.8      Governing Law. This Agreement and any claim, controversy or dispute arising out of or related to this Agreement, any of the Transactions, the relationship of the Parties, and/or the interpretation and enforcement of the rights and duties of the Parties, whether arising in contract, tort, equity or otherwise, shall be governed by and construed in accordance with the domestic Laws of the State of Delaware (including in respect of the statute of limitations or other limitations period applicable to any such claim, controversy or dispute), without giving effect to any choice or conflict of Law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware.

 9.9       Amendments and Waivers. No amendment of any provision of this Agreement shall be valid unless the same shall be in writing and signed by Investor and Orgenesis Parent. No waiver by any Party of any provision of this Agreement or any default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional or not, shall be valid unless the same shall be in writing and signed by the Party making such waiver nor shall such waiver be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence.

 9.10      Injunctive Relief. The Parties hereby agree that, in the event of breach of Sections 4.1, 4.3, 4.4, 4.5, or 4.6 of this Agreement, damages would be difficult, if not impossible, to ascertain, that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached, and that the character, periods and geographical area and the scope of the restrictions on Orgenesis Parent’s activities in Sections 4.4, 4.5 and 4.6 are fair and reasonably required for the protection of Investor and its Affiliates. It is accordingly agreed that, in addition to and without limiting any other remedy or right it may have, Investor shall be entitled to an injunction or other equitable relief in any court of competent jurisdiction, without any necessity of proving damages or any requirement for the posting of a bond or other security, enjoining any such breach of Sections 4.1, 4.3, 4.4, 4.5, or 4.6 and enforcing specifically the terms and provisions. Orgenesis Parent and Investor hereby (a) waives any and all defenses it may have on the ground of lack of jurisdiction or competence of the court to grant such an injunction or other equitable relief and (b) acknowledges that Orgenesis Parent and Investor shall receive significant benefits as a result of the completion of the Transactions.

-57-


 9.11       Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction.

 9.12       Expenses. Except as otherwise expressly provided in this Agreement, each Party will bear its own costs and expenses (including legal fees and expenses) incurred in connection with this Agreement and the Transactions; provided, that (a) all Orgenesis Transaction Expenses shall be paid by Orgenesis Parent and (b) upon consummation of the Transactions, the Investor Expenses will be assumed and paid by the Company up to an amount not to exceed $1,500,000.

 9.13      Construction. The Parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement. Any reference to any Law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. The word “including” shall mean including without limitation.

 9.14       Incorporation of Exhibits and Disclosure Schedule. The Exhibits, Disclosure Schedule and other Schedules identified in this Agreement are incorporated herein by reference and made a part hereof.

 9.15      Schedules. Any item or information set forth in the Disclosure Schedule shall be deemed fully disclosed to the extent the relevance of such item or information is reasonably apparent from the face of such disclosure. The Parties intend that each representation, warranty, and covenant contained herein shall have independent significance. If any Party has breached any representation, warranty or covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless of the relative levels of specificity) which the Party has not breached shall not detract from or mitigate the fact that the Party is in breach of the first representation, warranty, or covenant. Investor has been provided full and complete copies of all documents referred to on the Disclosure Schedule. The Investor shall have no recourse of any kind against Orgenesis Parent, the Company or any of their Subsidiaries pursuant to Section 6.1(a)(i) with respect matters or items that are properly disclosed as exceptions to such representation and warranty in the applicable section(s) of the Disclosure Schedule and in accordance with this Section 9.15.

 9.16      Waiver of Jury Trial. EACH OF THE PARTIES WAIVES THEIR RESPECTIVE RIGHTS TO A TRIAL BY JURY OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OR RELATED TO THIS AGREEMENT IN ANY ACTION, PROCEEDING OR OTHER LITIGATION OF ANY TYPE BROUGHT BY ANY OF THE PARTIES AGAINST ANY OTHER PARTY OR ANY AFFILIATE OF ANY OTHER SUCH PARTY, WHETHER WITH RESPECT TO CONTRACT CLAIMS, TORT CLAIMS OR OTHERWISE. THE PARTIES AGREE THAT ANY SUCH CLAIM OR CAUSE OF ACTION SHALL BE TRIED BY A COURT TRIAL WITHOUT A JURY. WITHOUT LIMITING THE FOREGOING, THE PARTIES FURTHER AGREE THAT THEIR RESPECTIVE RIGHT TO A TRIAL BY JURY IS WAIVED BY OPERATION OF THIS SECTION AS TO ANY ACTION, COUNTERCLAIM OR OTHER PROCEEDING WHICH SEEKS, IN WHOLE OR IN PART, TO CHALLENGE THE VALIDITY OR ENFORCEABILITY OF THIS AGREEMENT OR ANY PROVISION HEREOF. THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT.

-58-


 9.17       Exclusive Venue. THE PARTIES AGREE THAT ALL DISPUTES, LEGAL ACTIONS, SUITS AND PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT MUST BE BROUGHT EXCLUSIVELY IN A FEDERAL DISTRICT COURT LOCATED IN THE DISTRICT OF DELAWARE OR THE DELAWARE CHANCERY COURT IN NEW CASTLE COUNTY, DELAWARE (COLLECTIVELY THE “DESIGNATED COURTS”). EACH PARTY HEREBY CONSENTS AND SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE DESIGNATED COURTS. NO LEGAL ACTION, SUIT OR PROCEEDING WITH RESPECT TO THIS AGREEMENT MAY BE BROUGHT IN ANY OTHER FORUM. EACH PARTY HEREBY IRREVOCABLY WAIVES ALL CLAIMS OF IMMUNITY FROM JURISDICTION AND ANY OBJECTION WHICH SUCH PARTY MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR PROCEEDING IN ANY DESIGNATED COURT, INCLUDING ANY RIGHT TO OBJECT ON THE BASIS THAT ANY DISPUTE, ACTION, SUIT OR PROCEEDING BROUGHT IN THE DESIGNATED COURTS HAS BEEN BROUGHT IN AN IMPROPER OR INCONVENIENT FORUM OR VENUE. EACH OF THE PARTIES ALSO AGREES THAT DELIVERY OF ANY PROCESS, SUMMONS, NOTICE OR DOCUMENT TO A PARTY HEREOF IN COMPLIANCE WITH SECTION 9.7 SHALL BE EFFECTIVE SERVICE OF PROCESS FOR ANY ACTION, SUIT OR PROCEEDING IN A DESIGNATED COURT WITH RESPECT TO ANY MATTERS TO WHICH THE PARTIES HAVE SUBMITTED TO JURISDICTION AS SET FORTH ABOVE.

 9.18       Time to Bring Claims. Pursuant to Section 8106, Title 10 of the Delaware Code, the Parties agree that this Agreement involves at least U.S. $100,000, and that any Proceeding arising out of or relating to this Agreement or the Transactions may be brought at any time within 10 years following the date on which there is a Change of Control Transaction of the Company (as hereinafter defined); it being the intention of the Parties that, except as otherwise expressly provided in this Agreement with respect to shorter periods of time, the Parties shall have the maximum amount of time permitted under the Laws of the State of Delaware to bring a Proceeding arising out of or relating to this Agreement or the Transactions. Except as otherwise expressly provided in Section 6.3 with respect to shorter periods of time, each Party hereby waives the right to assert any statute of limitations of less than 10 years following the date of a Change of Control Transaction of the Company in defense of any such Proceeding; provided, however, that this waiver shall not bar a defense to any Proceeding that was not commenced within the 10 year time limit imposed by this Section 9.18. For the purposes of this Section 9.18, the term “Change of Control Transaction” shall mean the following: (i) the sale of all, or substantially all, of the assets of the Company to a third party that is unrelated to the Company or its stockholders; (ii) a merger with or into or consolidated with another entity under circumstances where the stockholders of the Company immediately prior to such merger or consolidation do not own after such merger or consolidation shares representing at least fifty percent (50%) of the voting power of the Company or the surviving or resulting entity, as the case may be; or (iii) an acquisition of more than 50% of the outstanding equity of the Company by a third party that is unrelated to the Company or its stockholders.

-59-


[Remainder of Page Intentionally Left Blank]

-60-


IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above written.

INVESTOR:
   
GPP-II MASTHERCELL, LLC
   
By:  
Name:  
Title:  
   
COMPANY:
 
MASTHERCELL GLOBAL INC.
   
By:  
Name:  
Title:  
   
ORGENESIS PARENT:
 
ORGENESIS INC.
   
By:  
Name:  
Title:  

[SIGNATURE PAGE TO STOCK PURCHASE AGREEMENT]